

CONTRACEPTION

INDEX TO VOLUME 21

AUTHOR INDEX

Abdel-Gawad, A.H.E., 479
Abdel-Hay, M.M., 479
Allonen, H., 321
Amatayakul, K., 283
Andrade, A.T.L., 343
Angelo, S., 585
Aubert, J.M., 577
Babu, S., 53
Back, D.J., 135, 145
Baggett, B., 115
Bain, J., 365
Baumann, R., 191
Benoit, H.J., 41
Beuving, D.C., 353
Bolt, H.M., 145
Boots, L.R., 659
Boria, M.D., 577
Borth, R., 41
Brekenridge, A.M., 135, 145
Bruzzone, M.E., 585
Bygeman, M., 571
Carenza, L., 311
Casper, R.F., 471
Chang, M.C., 77, 461
Channiniyom, K., 299
Crawford, F.E., 135, 145
Custo, G.M., 311
Damgaard-Pedersen, F., 381
de la Pena, A., 1, 17
Demers, L.M., 551
de Souza, J.P., 343
Dhawan, B.N., 29
Diczfalusy, E., 87, 415
Dozier, T.S., 1, 17
Dusitsin, N., 299
El-Sawy, M., 479
Engineer, A.D., 29
Etchell, D.M., 335
Findley, W.E., 199
Foegh, M., 381, 631
Fortney, J.A., 235
Frankman, O., 571
Freund, H., 641
Gentzschein, E., 595
Gibor, Y., 491
Ghosh, T., 183
Gobeaux-Castadot, M.-J., 577
Goldzieher, J.W., 1, 17
Goncharov, N.P., 537
Goresky, D.M., 335
Gormsen, J., 381
Green, K., 571
Greenspan, A.R., 563
Guirgis, F.K., 479
Gupta, G.N., 165
Gupta, K., 617
Gutknecht, G.D., 353
Gu, Z., 461
Hahn, D.W., 529, 551
Hall, J.M., 135
Hammerstein, J., 393
Hasan, M., 433
Hatcher, R.A., 563
Hazari, K., 617
Hesse, G., 641
Honore, L.H., 47
Islam, F., 433
Jacobs, B.R., 199
Jahan, F.A., 207
Joshi, J.V., 617
Joshi, U.M., 165, 617
Kamboj, V.P., 29
Khait, Z., 365
Kahn, A.R., 207
Khanna, N.M., 29
Kholkute, S.D., 165
Knecht, M., 425
Knudsen, J.B., 381
Koh, S., 505
Kuhl, H., 191
Kurischko, A., 61, 537
Kutty, D., 29
Lahteenmaki, P., 155, 225
Landgren, B.-M., 87, 415
Lau, I.F., 77
Lauersen, N.H., 273
Leepipatpaiboon, S., 299
Lumkin, M., 595

CONTRACEPTION

Luukkainen, T., 155, 225, 321
Macaulay, L.K., 343
MacIver, M., 135
Maitra, A., 165
McConnell, R.F., 529
McGuire, J.L., 529, 551
Mehta, S., 217
Michaels, T., 175
Mishell, D.R., Jr., 595
Mitchell, C., 491
Moberg, P., 571
Moltz, L., 393
Moore, M., 563
Munshi, S.R., 165
Nandi, R.C., 29
Nash, H.A., 115
Nayyar, S.K., 183
Nichol, K., 631
Nielsen, N.-C., 321
Nilsson, C.G., 155, 225
Nygren, K.-G., 321
Oettel, M., 61, 537, 641
Oriowo, M.A., 415
Orme, M.L'E., 135, 145
Ory, H.W., 563
Osman, S.M., 433
Pala, A., 311
Petersen, I.B., 631
Post, K., 393
Prema, K., 53
Pyörälä, T., 321
Rachlis, V., 365
Ramalakshmi, B.A., 53
Rao, A.P., 617
Ratnam, S.S., 505
Rizvi, R., 433
Robert, E., 365
Römmler, A., 393
Rosenberg, M.J., 563
Rowe, P.H., 135, 145, 343
Sairam, M.R., 651
Saleh, F.M., 479
Sandberg, C.-G., 571
Sandow, J., 191
Sankolli, G.M., 617
Sarin, J.P.S., 29
Saxena, B.N., 217, 617
Schindler, A.E., 145
Schou, G., 381, 631
Schubert, K., 537
Schwartz, U., 393
Setty, B.S., 29
Shaw, S.T., Jr., 343
Sheehan, K., 471
Sheth, U.K., 617
Singh, L., 29
Singh, S., 29
Singkamani, R., 283
Sivassomboon, B., 283
Smith, E., 135
Smith, R.P., 335
Southern, E.M., 353
Spilman, C.H., 353
Stanczyk, F., 595
Stenström, B., 415
Strecke, J., 537
Subhas, T., 175
Swenson, I., 207
Taubert, H.-D., 191
Tejuja, S., 165
Toddywalla, V.S., 217
Tsakok, F.H.M., 505
Vaivanikul, B., 299
Vengadasalam, D., 235
Virkar, K.D., 217
Virutamasen, P., 299
Wang, C., 245
Watts, M.J., 135
Werawatgoomba, S., 299
WHO 121, 445
Williams, S.A., 659
Wilson, K.H., 273
Woolever, C.A., 41
Yen, S.S., 471
Yeung, K.K., 245
Zipper, J., 585

CONTRACEPTION

INDEX TO VOLUME 21

SUBJECT INDEX

Abnormal spermatozoa,
 effect of oral cyproterone acetate, 393
 effect of oral levo-norgestrel + monthly testosterone enanthate, 631
 effect of oral levo-norgestrel + testosterone, 381

Abortifacient effects, root of *Trichosarthis kirilowii* (mouse, rabbit, 77

Acceptability of drugs, male fertility regulation, 121

Actinomyces in endometrium, use of IUD, 577

Adverse effects, oral medroxyprogesterone acetate + methyltestosterone (male), 365

Alpha-feto protein levels, effect of oral contraceptive use, 53

Antagonistic activity, deglycosylated ovine LH (rat), 651

Anti-deciduogenic activity, STS 557 (rat), 537

Antifertility activity of hCG, species differences (mouse, rat, hamster), 551

Antigonadotropic activity, *Lithospermum ruderale*, 199

Antiprogestational properties, STS 557 (rabbit), 61

Anti-tubercular drugs, interaction of ethinyl estradiol + norethisterone acetate, 617

Aspartate aminotransferase activity in kidney and uterus,
 effect of ethynodiol (rat), 659
 effect of ethynodiol + norgestrel (rat), 659
 effect of norgestrel (rat), 659

Association of depo-medroxyprogesterone acetate and breast cancer, 563

Biabsorbable implant, norethisterone release (monkey), 165

Biodegradable implant,
 norethisterone, 217
 d-norgestrel, 217

3,5-Bis(dimethylamino)-1,2,4-dithiazolium chloride (ORF 5513),
 effect on ovulation (rat), 529
 effect on pregnancy (rat), 529

Bleeding and ovulation, effect of levonorgestrel-releasing IUD, 155

Bleeding episodes, subcutaneous rods containing levonorgestrel, 595

Bleeding pattern,
 levonorgestrel-releasing IUD, 225
 norethisterone minipill, 87
 subcutaneous rods containing levonorgestrel, 595

Bleeding/pain, effect of progesterone-releasing IUD, 491

Blood coagulation tests, effect of oral contraceptives containing 50 µg estrogen, 505

Brain, regional lipid levels after ethynodiol + norgestrel (rabbit), 433

Breast cancer,
 association of depo-medroxyprogesterone acetate, 563
 relative risk of oral contraceptive use, 563

Breast milk, effect of different drug delivery systems on levels of contraceptive steroids, 217

Carbohydrate metabolism, effect of medroxyprogesterone acetate, 283

CONTRACEPTION

Cardiovascular disease and serum lipoproteins, effects of contraceptive steroids, 115
Cervical dilatation prior to vacuum aspiration, vaginal 15-methyl-PGF_{2α} methyl ester suppository, 571
Cervical dilator, use of Isaptent, 29
Choriocarcinoma implant, effect of hCGβ-tt immunization on ovarian morphology (hamster), 425
Clinical and endocrinologic study, subcutaneous rods containing levonorgestrel, 595
Clinical examination, oral cyproterone acetate (male), 245
Coagulation factors, effect of oral levo-norgestrel + testosterone (male), 381
Combination oral male contraceptive, levo-norgestrel + testosterone, 381
medroxyprogesterone acetate + methyltestosterone, 365
Comparative study, ethinyl estradiol + norethisterone acetate vs. estradiol + norethisterone acetate, 445
norethindrone enanthate vs. depo-medroxyprogesterone acetate, 207
Nova T and Cooper T 200, 321
Complaints reported, ethinyl estradiol + norethisterone acetate vs. estradiol + estriol + norethisterone acetate, 445
Contraceptive steroid release through different drug delivery systems into serum and breast milk, 217
Contraceptive steroids, effect on serum lipoproteins and cardiovascular disease, 115
Contracestational properties, STS 557 (rabbit), 61
Copper 7, Actinomycetes in endometrium, 577
Copper IUD, five years experience in nulliparous women, 335
Copper T, quantitative menstrual and intermenstrual blood loss, 343
Cooper T 200 and Nova T, comparative study, 321
Copper-releasing IUD, Nova T and Copper T 200, 321
17α-Cyanomethyl-17β-hydroxy-estra-4,9(10)-diene-3-one (STS 557),
anti-decidiogenetic activities (rat), 537
antiprogestational properties (rabbit), 61
contracestational properties (rabbit), 61
effect on fertility (male rabbit), 641
effect on maintenance of early pregnancy (rat), 537
effect on semen characteristics (rabbit), 641
effect on sexual behavior (male rabbit), 641
interceptive action (mouse, rat, guinea pig, baboon), 537
orally active progestin (rabbit), 61
Cyproterone acetate,
acceptability for male fertility regulation, 121
effect on hormone secretion (male), 393
effect on organ weights (rat), 183
effect on spermatogenesis, 393
hormonal measurements (male), 245
oral male contraceptive, 245, 393
seminal fluid analyses, 245

CONTRACEPTION

Cyproterone acetate and seminal vesicles, regulation of male fertility (rat), 183

Dalkon Shield, *Actinomyces* in endometrium, 577

Deglycosylated ovine LH, effect on LH-induced ovulation (rat), 651

Depo-medroxyprogesterone acetate, association of breast cancer, 563

Depo-medroxyprogesterone acetate vs. norethindrone enanthate, randomized, single blind comparative trial, 207

Depot-medroxyprogesterone acetate,
effect on liver function tests, 479
effect on serum phospholipid fractionation, 479

Depot-medroxyprogesterone acetate + testosterone cypionate, acceptability for male fertility regulation, 121

Detection of ovulation, electrochemical vaginal-oral potentials, 585

Detection of pre-ovulatory period, use of vaginal probe, 41

Different populations,
plasma levels and pharmacokinetics of ethynodiol, 1
plasma levels and pharmacokinetics of mestranol, 17

Dihydrotestosterone level,
effect of oral cyproterone acetate (male), 393
effect of oral medroxyprogesterone acetate + methyltestosterone (male), 365

Dilatation of cervix, use of Isapent, 29

Dilatation of cervix prior to vacuum aspiration, vaginal 15-methyl-PGF_{2α} methyl ester suppository, 571

Discontinuation,
effect of oral levo-norgestrel + monthly testosterone enanthate (male), 651
norethindrone enanthate vs. depo-medroxyprogesterone acetate, 207

Discontinuation rates, ethinyl estradiol + norethisterone acetate vs. estradiol + estriol + norethisterone acetate, 445

Disposable menstrual regulation kits, durability in non-throw-away economy, 235

Drug delivery systems, effect on levels of contraceptive steroids in serum and breast milk, 217

Durability of disposable menstrual regulation kits, non-throw-away economy, 235

Early pregnancy interruption, two 15-ME-PGF_{2α} suppositories, 273

Electrochemical vaginal-oral potentials, changes during menstrual cycle, 585

Endocrinologic and clinical study, subcutaneous rods containing levonorgestrel, 595

Endometrial biopsies, subcutaneous rods containing levonorgestrel, 595

Estradiol + estriol + norethisterone acetate vs. ethinyl estradiol + norethisterone acetate, randomized, double-blind study, 445

Estradiol and estrone levels, intramuscular administration of various estradiol esters, 415

Estradiol benzoate,
pharmacokinetic properties, 415
plasma levels of estradiol and estrone, 415

Estradiol cypionate,
pharmacokinetic properties, 415
plasma levels of estradiol and estrone, 415

CONTRACEPTION

Estradiol esters, pharmacokinetic properties, 415
Estradiol level,
 effect of daily administration of HOE 766 (LH-RH analog), 191
 effect of injectable norethisterone oenanthate, 299
 effect of levonorgestrel-releasing IUD, 155, 225
 effect of LRF-agonist (D-Trp⁶, Pro⁹ NET)-LRF and hCG, 471
 effect of oral cyproterone acetate (male), 245
 norethisterone minipill, 87
 subcutaneous rods containing levonorgestrel, 595
Estradiol valerate,
 pharmacokinetic properties, 415
 plasma levels of estradiol and estrone, 415
Estrogen level, effect of hCG during pregnancy (rat), 551
Estrogen-containing oral contraceptives, effect on blood coagulation, 505
Ethynodiol-17 β , effect on uterine and kidney aspartate aminotransferase activity (rat), 659
Ethynodiol-17 β + levonorgestrel treatment, pharmacokinetic properties of estradiol esters, 415
Ethynodiol-17 β + norethisterone, levels in serum and breast milk, 217
Ethynodiol-17 β + norethisterone acetate,
 effect of anti-tubercular drugs, 617
 effect of isonicotinic acid hydrazide treatment, 617
 effect of paraaminosalicylic acid treatment, 617
 effect of Rifampicin treatment, 617
Ethynodiol-17 β + norethisterone acetate vs. estradiol + estriol + norethisterone acetate, randomized, double-blind study, 445
Ethynodiol-17 β + norgestrel,
 effect on regional lipid levels of brain (rabbit), 433
 effect on uterine and kidney aspartate aminotransferase activity (rat), 659
 levels in serum and breast milk, 217
Ethynodiol-17 β levels, effect of anti-tubercular drugs, 617
Ethynodiol-17 β ,
 effect of Rifampicin on pharmacokinetics, 135
 pharmacokinetics, 1, 145
 plasma levels, 1
Ethynodiol-17 β + injectable norethisterone oenanthate, effect on ovarian hormones, 299
Ethynodiol-17 β + norethindrone acetate, effect of Rifampicin on pharmacokinetics, 135
Ethynodiol-17 β + norgestrel, effect on plasma alpha-feto protein levels, 53
Ethynodiol-17 β + norgestrel + injectable norethisterone oenanthate, effect on ovarian hormones, 299
Ethynodiol-17 β glucuronide level, large oral dose ethynodiol, 145
Ethynodiol-17 β levels, pharmacokinetics of mestranol, 17
Ethynodiol-17 β sulphate level, large oral dose ethynodiol, 145
Expulsion, effect of progesterone-releasing IUD, 491
Fertility, effect of STS 557 (male rabbit), 641

CONTRACEPTION

Fibrinolytic activity and capacity,
effect of oral levo-norgestrel + monthly testosterone enanthate
(male), 631
effect of oral levo-norgestrel + testosterone (male), 381

Fibrinolytic tests, effect of oral contraceptives containing 50 µg
estrogen, 505

Five years experience, copper IUDs in nulliparous women, 335

Follicle stimulating hormone (FSH),
Fructose content in semen, effect of STS 557 (rabbit), 641

FSH (follicle stimulating hormone)
FSH level,
effect of daily administration of HOE 766 (LH-RH analog), 191
effect of levonorgestrel-releasing IUD, 155, 225
effect of oral cyproterone acetate (male), 245, 393
effect of oral levo-norgestrel + monthly testosterone enanthate (male),
631
effect of oral levo-norgestrel + testosterone (male), 381
effect of oral medroxyprogesterone acetate + methyltestosterone (male),
365
effect of progesterone-releasing IUD, 311

Glucose tolerance test, effect of medroxyprogesterone acetate, 283

Gossypol acetic acid, effect on male fertility (rat, hamster, rabbit), 461

hCG (human chorionic gonadotropin)
hCG level,
effect of 15-ME-PGF_{2α} suppository, 273
effect of progesterone-releasing IUD, 311
vaginal suppository containing 15(S)-15-methyl-PGF_{2α} methyl ester, 353

hCG_β-tt(beta subunit of human chorionic gonadotropin coupled to tetanus
toxoid),
hCG_β-tt immunization, effect on ovarian morphology when implanted with
human choriocarcinoma (hamster), 425

Heating of scrotum prior to vasectomy,
influence on sperm granuloma formation, 175
influence on testicular activity, 175

Heteroploid-correlated structural abnormalities in spontaneous abortuses,
effect of IUD, 47

HOE 766 (D-Ser(TBU)₆-LH-RH-(1-9)-nonapeptide-ethylamide, LH-RH analog)

Home use of vaginal probe, detection of pre-ovulatory period, 41

Hormonal antagonist, deglycosylated ovine LH (rat), 651

Hormonal effects, norethisterone minipill, 87

Hormonal measurements, oral cyproterone acetate (male), 245

Hormone levels, effect of oral levo-norgestrel + testosterone (male), 381

Hormone profiles, levonorgesterel-releasing IUD, 225

Hormone secretion, effect of oral cyproterone acetate (male), 393

Human chorionic gonadotropin (hCG),
effect on luteolytic action of LRF-agonist (D-Trp⁶,Pro⁹NET)-LRF, 471
mechanism of antifertility activity (rat), 551

17 α -Hydroxyprogesterone caproate + testosterone oenanthate, acceptability
for male fertility regulation, 121

Immunization with hCG_β-tt, effect on ovarian morphology when implanted
with human choriocarcinoma (hamster), 425

Implant, levonorgestrel rods, 595

Implantation sites of females, effect of male treated with Gossypol acetic
acid (rat, hamster), 461

CONTRACEPTION

Implantation with human choriocarcinoma, effect of hCG β -tt immunization on ovarian morphology (hamster), 425
Induction of menses, vaginal 15(S)-15-methyl-PGF 2α methyl ester suppository, 353
Inhibition of LH-induced ovulation, effect of deglycosylated ovine LH (rat), 651
Inhibition of ovulation, daily administration of HOE 766 (LH-RH analog), 191
Injectable contraceptive,
 depo-medroxyprogesterone acetate, 207, 563
 depot-medroxyprogesterone acetate, 479
 medroxyprogesterone acetate, 283
 norethindrone enanthate, 207
 norethisterone enanthate, 299, 479
Injectable norethisterone enanthate, effect on ovarian hormones, 299
Injectable norethisterone enanthate + ethynodiol, effect on ovarian hormones, 299
Injectable norethisterone enanthate + ethynodiol + norgestrel, effect on ovarian hormones, 299
Insertion problems, copper IUDs in nulliparous women, 325
Interaction of low-dose combination oral contraceptive with anti-tubercular drugs, 617
Interceptive action, STS 557 (mouse, rat, guinea pig, baboon), 537
Intermenstrual blood loss, Lippes loop C and copper T, 343
Intramuscular administration of estradiol esters, pharmacokinetic properties, 415
Intrauterine contraceptive device (IUD),
 copper, 335
 copper T, 343
 copper T 200, 321
 effect on morphologic abnormalities in spontaneous abortions, 47
 levonorgestrel-releasing, 155, 225
 Lippes loop C, 343
 Nova T, 321
 progesterone-releasing, 311, 491
Isaptent, cervical dilator made from Plantago ovata seed husk powder, 29
Isonicotinic acid hydrazide, interaction of ethinyl estradiol + norethisterone acetate, 617
IUD (intrauterine contraceptive device)
IUD users, *Actinomyces* in endometrium, 577
Kidney aspartate aminotransferase activity,
 effect of ethynodiol (rat), 659
 effect of ethynodiol + norgestrel (rat), 659
 effect of norgestrel (rat), 659
Large oral dose (3 mg) ethynodiol, pharmacokinetics, 145
Levo-norgestrel + testosterone,
 effect on coagulation factors (male), 381
 effect on hormone levels (male), 381
 effect on lipoproteins (male), 381
 effect on spermatogenesis, 381
 oral male contraceptive, 381

CONTRACEPTION

Levo-norgestrel + testosterone enanthate, clinical evaluation of long-term treatment (male), 631
Levonorgestrel level,
 effect of levonorgestrel-releasing IUD, 155, 225
 subcutaneous rods containing levonorgestrel, 595
Levonorgestrel-containing subcutaneous rods, clinical and endocrinologic study, 595
Levonorgestrel-releasing IUD,
 pattern of bleeding, 225
 patterns of ovulation and bleeding, 155
 plasma concentrations and hormone profiles, 225
LH (luteinizing hormone)
LH level,
 effect of daily administration of HOE 766 (LH-RH analog), 191
 effect of levonorgestrel-releasing IUD, 155, 225
 effect of oral cyproterone acetate (male), 245, 393
 effect of oral levo-norgestrel + monthly testosterone enanthate (male), 631
 effect of oral levo-norgestrel + testosterone (male), 381
 effect of oral medroxyprogesterone acetate + methyltestosterone (male), 365
 effect of progesterone-releasing IUD, 311
LH-induced ovulation, effect of deglycosylated ovine LH (rat), 651
LH-RH (luteinizing hormone releasing hormone),
LH-RH analog (D-Ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide = HOE 766),
 ovulation inhibition by daily administration, 191
LH-RH double stimulation, effect of oral cyproterone acetate (male), 393
Lipids, effect of medroxyprogesterone acetate, 283
Lipids in discrete brain areas, effect of ethynodiol + norgestrel (rabbit), 433
Lipoproteins, effect of oral levo-norgestrel + testosterone (male), 381
Lipoproteins and cardiovascular disease, effect of contraceptive steroids, 115
Lippes loop, *Actinomyces* in endometrium, 577
Lippes loop C, quantitative menstrual and intermenstrual blood loss, 343
Lithospermum ruderale,
 antigonadotropic activity, 199
 effect on steroid receptors, 199
Liver function tests,
 effect of medroxyprogesterone acetate, 283, 479
 effect of norethisterone oenanthate, 479
Long-term treatment with levo-norgestrel + testosterone enanthate (male), 631
LRF (luteinizing hormone releasing factor)
LRF-agonist (D-Trp⁶,Pro⁹NEt)-LRF,
 effect of hCG on luteolytic action, 471
 effect on serum levels of β -hCG, estradiol and progesterone following three doses, 471
 effect on serum levels of β -hCG, estradiol and progesterone in early pregnancy, 471
Luteinizing hormone (LH)
Luteinizing hormone releasing factor (LRF)

CONTRACEPTION

Luteinizing hormone releasing hormone (LH-RH)
Luteolytic action of LRF-agonist (D-Trp⁶,Pro⁹NET)-LRF, effect of hCG, 471
Maintenance of early pregnancy, STS 557 (rat), 537
Maintenance of pregnancy during hCG treatment, effect of progesterone, anti-hCG and ovariectomy (rat), 551
Male contraceptive,
 oral cyproterone acetate, 245, 393
 oral levo-norgestrel + monthly testosterone enanthate, 631
 oral levo-norgesterol + testosterone, 381
 oral medroxyprogesterone acetate + methyltestosterone, 365
Male fertility, effect of Gossypol acetic acid (rat, hamster, rabbit), 461
Male fertility regulation,
 acceptability of drugs, 121
 cyproterone acetate and seminal vesicles (rat), 183
 measurement of sexual functioning, 121
Male user's evaluations of hormonal methods, 121
Mechanism of antifertility activity, hCG (rat), 551
Medroxyprogesterone acetate, effect on serum lipids, protein, glucose
 tolerance and liver function, 283
Medroxyprogesterone acetate + methyltestosterone,
 acceptability for male fertility regulation, 121
 oral male contraceptive, 365
Medroxyprogesterone acetate + testosterone oenanthate, acceptability for
 male fertility regulation, 121
Menses induction, vaginal 15(S)-15-methyl-PGF_{2α} methyl ester suppository, 353
Menstrual and intermenstrual blood loss, Lippes loop C and copper T, 343
Menstrual complaints, ethinyl estradiol + norethisterone acetate vs.
 estradiol + estriol + norethisterone acetate, 445
Menstrual cycle, measurement of electrochemical vaginal-oral potentials, 585
Menstrual irregularities, ethinyl estradiol + norethisterone acetate vs.
 estradiol + estriol + norethisterone acetate, 445
Menstrual patterns, norethindrone enanthate vs. depo-medroxyprogesterone
 acetate, 207
Menstrual regulation kits in non-throw-away economy, 235
15-ME-PGF_{2α} (15(S)-15-methyl-prostaglandin F_{2α})
15-ME-PGF_{2α} level, 15-ME-PGF_{2α} suppositories for early pregnancy interruption, 273
Mestranol,
 pharmacokinetics, 17
 plasma levels, 17
15-Methyl-PGF_{2α} methyl ester, vaginal suppository for dilatation of cervix
 prior to vacuum aspiration, 571
15-Methyl-PGF_{2α} plasma concentration, vaginal suppository containing 15(S)-
 15-methyl-PGF_{2α} methyl ester, 353
Methyltestosterone + medroxyprogesterone acetate,
 acceptability for male fertility regulation, 121
 oral male contraceptive, 365

CONTRACEPTION

Minipill, norethisterone, 87
Morphologic abnormalities in spontaneous abortions, effect of IUD, 47
Non-Caucasian women, effects of oral contraceptives containing 50 μ g
estrogen on blood coagulation, 505
Non-throw-away economy, use of disposable menstrual regulation kits, 235
Norethindrone enanthate vs. depo-medroxyprogesterone acetate, randomized,
single blind comparative trial, 207
Norethindrone level, effect of injectable norethisterone oenanthate, 299
Norethisterone, levels in serum and breast milk, 217
Norethisterone + cholesterol,
 bioabsorbable implant (monkey), 165
 biodegradable implant, 217
Norethisterone level,
 effect of anti-tubercular drugs, 617
 norethisterone minipill, 87
 norethisterone release from bioabsorbable implant (monkey), 165
Norethisterone minipill, hormonal effects, 87
Norethisterone oenanthate,
 effect on liver function tests, 479
 effect on ovarian hormones, 299
 effect on serum phospholipid fractionation, 479
Norethisterone oenanthate in Thai women, 299
Norethisterone oenanthate level, effect of injectable norethisterone
oenanthate, 299
Norethisterone release, bioabsorbable implant (monkey), 165
Norgestrel, effect on uterine and kidney aspartate aminotransferase
activity (rat), 659
d-Norgestrel, levels in serum and breast milk, 217
d-Norgestrel + cholesterol, biodegradable implant, 217
Nova T and copper T 200, comparative study, 321
Nulliparous women, five years experience with copper IUDs, 335
Oral contraceptive,
 effect on plasma alpha-feto protein levels, 53
 estradiol + estriol + norethisterone acetate, 445
 ethinyl estradiol + norethisterone, 217
 ethinyl estradiol + norethisterone acetate, 445, 617
 ethinyl estradiol + d-norgestrel, 217
 ethynodiol + norethindrone acetate, 135
 ethynodiol + norgestrel, 53
 norethisterone, 87, 217
 d-norgestrel, 217
Oral contraceptive use, relative risk of breast cancer, 563
Oral contraceptive users, measurement of electrochemical vaginal-oral
potentials, 585
Oral contraceptives, effect on serum lipoproteins and cardiovascular
disease, 115
Oral contraceptives containing 50 μ g estrogen,
 effect on blood coagulation, 505
 effect on fibrinolytic tests, 505
 effect on platelet function, 505

CONTRACEPTION

Oral male contraceptive,
 cyproterone acetate, 245, 393
 levo-norgestrel + testosterone, 381
 medroxyprogesterone acetate + methyltestosterone, 365
ORF 5513 (3,5-bis(dimethylamino)-1,2,4-dithiazolium chloride)
Ovarian hormones, effect of injectable norethisterone oenanthate, 299
Ovarian morphology, effect of hCG-tt immunization and implantation with
 human choriocarcinoma (hamster), 425
Ovulation, effect of ORF 5513 (rat), 529
Ovulation and bleeding, effect of levonorgestrel-releasing IUD, 155
Ovulation detection, electrochemical vaginal-oral potentials, 585
Ovulation inhibition, daily administration of HOE 766 (LH-RH analog), 191
Paraaminosalicylic acid treatment, interaction of ethynodiol +
 norethisterone acetate, 617
Pelvic inflammatory disease, effect of progesterone-releasing IUD, 491
PGF_{2α} (prostaglandin F_{2α})
Pharmacokinetic properties,
 estradiol benzoate, 415
 estradiol cypionate, 415
 estradiol esters, 415
 estradiol valerate, 415
Pharmacokinetics,
 ethynodiol, 1, 145
 mestranol, 17
Pharmacokinetics of ethynodiol, effect of Rifampicin, 135
Phospholipid fractionation,
 effect of depot-medroxyprogesterone acetate, 479
 effect of norethisterone oenanthate, 479
Plantago ovata, use in cervical dilator Isaptent, 29
Plasma alpha-feto protein levels, effect of oral contraceptive use, 53
Plasma concentrations of levonorgestrel, levonorgestrel-releasing IUD,
 225
Plasma levels,
 ethynodiol, 1
 mestranol, 17
Platelet aggregation,
 effect of oral levo-norgestrel + monthly testosterone enanthate (male),
 631
 effect of oral levo-norgestrel + testosterone (male), 381
Platelet function, effect of oral contraceptives containing 50 µg estrogen,
 505
Population difference,
 plasma levels and pharmacokinetics of ethynodiol, 1
 plasma levels and pharmacokinetics of mestranol, 17
Postabortal insertion, Nova T and copper T 200 comparative study, 321
Postmenstrual insertion, Nova T and copper T 200 comparative study, 321
Pregnancy,
 effect of ORF 5513 (rat), 529
 effect of progesterone-releasing IUD, 491
Pregnancy and implantation, effect of male treated with Gossypol acetic
 acid (rabbit), 461

CONTRACEPTION

Pregnancy interruption, two 15-ME-PGF_{2α} suppositories, 273
Pregnancy termination,
 dilatation of cervix prior to vacuum aspiration with 15-methyl-PGF_{2α}
 methyl ester, 571
 effect of Trichosanthin (mouse, rabbit), 77
 use of cervical dilator Isaptent, 29
Pre-ovulatory period detection, use of vaginal probe, 41
Prevalence of morphologic abnormalities in spontaneous abortions, effect
 of IUD, 47
Progesterone level,
 effect of daily administration of HOB 766 (LH-RH analog), 191
 effect of hCG during pregnancy (rat), 551
 effect of injectable norethisterone oenanthate, 299
 effect of levonorgestrel-releasing IUD, 225
 effect of LRF-agonist (D-Trp⁶,Pro⁸(NET)-LRF and hCG, 471
 effect of 15-ME-PGF_{2α} suppository, 273
 effect of progestrone-releasing IUD, 311
 norethisterone minipill, 87
 norethisterone release from bioabsorbable implant (monkey), 165
 subcutaneous rods containing levonorgestrel, 595
 vaginal suppository containing 15(S)-15-methyl-PGF_{2α} methyl ester,
 353
Progesterone-releasing IUD,
 effect on bleeding/pain, 491
 effect on expulsions, 491
 effect on pelvic inflammatory disease, 491
 levels of hCG, 311
 pregnancies, 491
 removals, 491
Prolactin level,
 effect of oral cyproterone acetate (male), 393
 large oral dose of ethynodiol, 145
Prostaglandin F_{2α} (PGF_{2α})
Protein, effect of medroxyprogesterone acetate, 283
Radioimmunoassay of norethisterone oenanthate, 299
Regional lipid levels of brain, effect of ethynodiol + norgestrel
 (rabbit), 433
Release of norethisterone, bioabsorbable implant (monkey), 165
Release rate of levonorgestrel, subcutaneous rods containing levonorgestrel,
 595
Removals, progestrone-releasing IUD, 491
Reproductive organ weights, effect of male treated with Gossypol acetic
 acid (rat, hamster), 461
Rifampicin, effect on pharmacokinetics of ethynodiol, 135
Rifampicin treatment, interaction of ethynodiol + norethisterone
 acetate, 617
Rods containing levonorgestrel, clinical and endocrinologic study, 595
15(S)-15-methyl-PGF_{2α} methyl ester, vaginal suppository for menses induction,
 353
15(S)-15-methyl-prostaglandin F_{2α} (15-ME-PGF_{2α}),
 comparison of one- and two-suppository regimen for early pregnancy
 interruption, 273

CONTRACEPTION

- Scrotal heating prior to vasectomy,
 - influence on ascorbic acid concentration (rat), 175
 - influence on sperm granuloma formation (rat), 175
 - influence on testicular activity (rat), 175
 - influence on testicular corticosterone (rat), 175
- Semen characteristics, effect of STS 557 (rabbit), 641
- Seminal fluid analyses, oral cyproterone acetate, 245
- Seminal fructose level, effect of oral cyproterone acetate, 393
- Seminal pH, effect of oral cyproterone acetate, 393
- Seminal vesicles and cyproterone acetate, regulation of male fertility (rat), 183
- Serum levels of contraceptive steroids, effect of different drug delivery systems, 217
- Sexual behavior, effect of STS 557 (male rabbit), 641
- Sexual functioning measurement, male fertility regulation, 121
- Sialic acid content in semen, effect of STS 557 (rabbit), 641
- Species differences, antifertility activity of hCG (mouse, Rat, hamster), 551
- Sperm count,
 - effect of oral cyproterone acetate, 393
 - effect of oral levo-norgestrel + monthly testosterone enanthate, 631
 - effect of oral levo-norgestrel + testosterone, 381
 - effect of oral medroxyprogesterone acetate + methyltestosterone, 365
 - effect of treatment with Gossypol acetic acid (rabbit), 461
- Sperm counts and sperm motility, effect of male treated with Gossypol acetic acid (rat, hamster), 461
- Sperm granuloma formation, influence of scrotal heating prior to vasectomy (rat), 175
- Sperm motility,
 - effect of oral cyproterone acetate, 393
 - effect of oral levo-norgestrel + monthly testosterone enanthate, 631
 - effect of oral medroxyprogesterone acetate + methyltestosterone, 365
- Spermatogenesis,
 - effect of oral cyproterone acetate, 393
 - effect of oral levo-norgestrel + testosterone, 381
- Spontaneous abortions, effect of IUD on morphologic abnormalities, 47
- Steroid receptors, effect of *Lithospermum ruderale*, 199
- STS 557 (17 α -cyanomethyl-17 β -hydroxy-*estr-4.9(10)-diene-3-one*)
 - Subcutaneous implant, cyproterone acetate in regulation of male fertility (rat), 183
- Subcutaneous rods containing levonorgestrel, clinical and endocrinologic study, 595
- Subdermal implant,
 - norethisterone, 217
 - norethisterone release from bioabsorbable implant (monkey), 165
 - d-norgestrel, 217
- Susceptibility of pregnancy, subcutaneous injection of hCG (rat), 551
- TCu users, measurement of electrochemical vaginal-oral potentials, 585
- Termination of early pregnancy, two 15-ME-PGF_{2 α} suppositories, 273

CONTRACEPTION

Termination of pregnancy,
dilatation of cervix prior to vacuum aspiration with 15-methyl-PGF_{2α} methyl ester, 571
effect of Trichosanthin (mouse, rabbit), 77
subcutaneous injection of hCG (rat), 551
use of cervical dilator Isaptent, 29

Termination rate,
five years experience with copper IUDs in nulliparous women, 335
Nova T and Copper T 200 comparative study, 321

Testicular activity, influence of scrotal heating prior to vasectomy (rat), 175

Testosterone + levo-norgestrel, oral male contraceptive, 381

Testosterone cypionate + depot-medroxyprogesterone acetate, acceptability for male fertility regulation, 121

Testosterone enanthate + levo-norgestrel, clinical evaluation of long-term treatment (male), 631

Testosterone level,
effect of oral cyproterone acetate (male), 245, 393
effect of oral levo-norgestrel + monthly testosterone enanthate (male), 631
effect of oral levo-norgestrel + testosterone (male), 381
effect of oral medroxyprogesterone acetate + methyltestosterone (male), 365

Testosterone oenanthate + 17α-hydroxyprogesterone caproate, acceptability for male fertility regulation, 121

Testosterone oenanthate + medroxyprogesterone acetate, acceptability for male fertility regulation, 121

Thai women, effect of injectable norethisterone oenanthate, 299

Toxicology, oral cyproterone acetate (male), 245

Trichosanthin-induced termination of pregnancy (mouse, rabbit), 77

Trichosanthis kirilowii, abortifacient effects from root extract (mouse, rabbit), 77

Two-year rates, Nova T and copper T 200 comparative study, 321

Uterine aspartate aminotransferase activity,
effect of ethynodiol (rat), 659
effect of ethynodiol + norgestrel (rat), 659
effect of norgestrel (rat), 659

Vacuum aspiration, dilatation of cervix with 15-methyl-PGF_{2α} methyl ester vaginal suppository, 571

Vaginal 15-ME-PGF_{2α} suppositories, early pregnancy interruption, 273

Vaginal 15-methyl-PGF_{2α} methyl ester suppository, dilatation of cervix prior to vacuum aspiration, 571

Vaginal probe, detection of pre-ovulatory period, 41

Vaginal 15(S)-15-methyl-PGF_{2α} methyl ester suppository, menses induction, 353

Vaginal-oral electrochemical potentials, changes during menstrual cycle, 585

Vasectomy,
influence of scrotal heating on sperm granuloma formation (rat), 175
influence of scrotal heating on testicular activity (rat), 175


Workshop, effects of contraceptive steroids on serum lipoproteins and cardiovascular disease, 115



VOL. 21 1980
JANUARY - JUNE
ISSN 0010-7824

CONTRACEPTION

AN INTERNATIONAL JOURNAL



DANIEL R. MISHELL, Jr., M.D.—Editor

Publisher: GERON-X, INC., LOS ALTOS, CALIF.

EDITOR

Daniel R. Mishell, Jr., M.D.
Dept. of Obstetrics and Gynecology
University of Southern California School of Medicine
1240 North Mission Road
Los Angeles, California 90033

EDITORIAL ASSISTANT

Elli J. Martin

BOARD OF ASSOCIATE EDITORS

Wendy Baldwin, Ph.D.
Behavioral Sciences Branch
Center for Population Research
National Institute of Child Health and Human Development
Bethesda, Maryland 20040

Gerald S. Bernstein, Ph.D., M.D.
Associate Professor
Department of Obstetrics and Gynecology
USC School of Medicine
Los Angeles, California 90033

M.C. Chang, Ph.D., Sc.D.
Senior Scientist
Worcester Foundation for Experimental Biology
Shrewsbury, Massachusetts 01545

Philip A. Cormfan, M.D.
Director of Population Research
National Institute of Child Health and Human Development
Bethesda, Maryland 20040

Ulwe Goebelsmann, M.D.
Director of the Reproductive Endocrinology Laboratory
Women's Hospital
1240 North Mission Road
Los Angeles, California 90033

Joseph W. Goldzieher, M.D.,
Director, Division of Clinical Sciences
Southwest Foundation for Research and Education
San Antonio, Texas 78228

Roy O. Greep, Ph.D.
Director
Laboratory of Human Reproduction & Reproductive Biology
Harvard Medical School
45 Shattuck Street
Boston, Massachusetts 02115

Roy Hertz, M.D., Ph.D.
Research Professor
Departments of Pharmacology and Obstetrics and Gynecology
George Washington University Medical Center
Washington, D.C. 20037

William D. Odell, M.D., Ph.D.
Professor and Chairman
Department of Medicine
Harbor General Hospital
U.C.L.A. School of Medicine
Torrance, California 90509

C. Alvin Paulsen, M.D.
Professor of Medicine
Department of Medicine
University of Washington School of Medicine
Seattle, Washington 98114

John J. Sciarra, M.D., Ph.D.
Chief of Staff
Prentice Women's Hospital and Maternity Center
333 East Superior Street
Chicago, Illinois 60611

Sheldon Segal, Ph.D.,
Director,
Population Division
Rockefeller Foundation
1133 Avenue of the Americas
New York, New York 10036

William N. Spillacy, M.D.
Professor and Head
Department of Obstetrics and Gynecology
The Abraham Lincoln School of Medicine
University of Illinois Medical Center
840 South Wood Street
Chicago, Illinois 60612

Howard J. Tatum, Ph.D., M.D.
Associate Director
Center for Biomedical Research
Rockefeller University
Yorke Avenue & 66th Street
New York, N.Y. 10021

Corresponding Editors for CONTRACEPTION

E. Coutinho, M.D.,
Professor
Department of Biochemistry and Obstetrics
University of Bahia
Salvador, Bahia, BRAZIL

P. G. Crognani, M.D.,
Professor Incarico di Endocrinologia Ginecologica alla Facolta di Medicina dell' Universita di Milano
Via Commenda 12
20122 Milano, ITALY

E. Diczfalusy, M.D.,
Professor
Reprod. Endocrinology Research Unit
Swedish Med. Research Council
Karolinska Sjukhuset
Stockholm 60, SWEDEN

J. Ferin, M.D.,
Professor
Physiology of Human Reprod. Research Unit
University of Louvain Hosp.
Louvain, BELGIUM

C. Guas, M.D.,
Instituto Nacional de la Nutricion
H. F. Cárdenas, Enfermedades de la Nutricion
Av. San Fernando y Viaducto Tlalpan
Mexico 22, D.F., MEXICO

I. Hallbrecht, M.D.,
Professor
Department of Obstetrics and Gynecology
Tel Aviv University Med. School
Tel Aviv, ISRAEL

J. Hammerstein, M.D.,
Professor
Abt. Gynäk. Endokrinologie
Sterilität und Familienplanung
Freie Universität Berlin
Hindenburghdamm 30
1000 Berlin 45

FED. REP. GERMANY

A. A. Haspels, M.D., Prof.
Department of Obstetrics and Gynecology
Academisch Med. University of Utrecht
Catherijnesingel 101

Utrecht, NETHERLANDS

T. Luukkainen, M.D.,
Steriod Research Laboratory
University of Helsinki
Department of Med. Chemistry
Siltavuorenpenner 10A
SF-00170 Helsinki 17,
FINLAND

J. R. Newton, M.D., Prof.
Birmingham Maternity Hospital
Queen Elizabeth Medical Centre
Edgbaston, Birmingham 15
ENGLAND

Badr N. Saxena, M.D.,
Deputy Director General
Indian Council of Medical Research
Ansari Nagar
New Delhi-110016, INDIA

R. P. Sherman, M.D.,
Professor of Obstetrics and Gynecology
The University of Sydney
Sydney 2006, N.S.W.
AUSTRALIA

M. Vessey, M.D.,
Professor, University Dept. of Social & Community Med.
University of Oxford
8 Kettle Road
Oxford, OX13QN
ENGLAND

J. Zanaru, M.D.,
Associate Professor
Department of Experimental Fertility
Universidad de Chile Clinica Obstetrica
Hospital Jose Joaquin Aguirre
Casilla 6637
Santiago, CHILE

CONTRACEPTION

January 1980

Volume 21, Number 1

Plasma Levels and Pharmacokinetics of Ethynodiol Estrogens in Various Populations	
I. Ethynodiol	
Goldzieher, J.W., Dozier, T.S. and de la Pena, A.	1
Plasma Levels and Pharmacokinetics of Ethynodiol Estrogens in Various Populations	
II. Mestranol	
Goldzieher, J.W., Dozier, T.S. and de la Pena, A.	17
Isapent - A New Cervical Dilator	
Khanna, N.M., Sarin, J.P.S., Nandi, R.C., Singh, S., Setty, B.S., Kamboj, V.P., Dhawan, B.N., Singh, L., Kutty, D. and Engineer, A.D.	29
Detection of the Pre-Ovulatory Period Using a Vaginal Probe in the Home	
Borth, R., Benoit, H.J. and Woolever, C.A.	41
The Effect of the Intrauterine Contraceptive Device on the Prevalence of Morphologic Abnormalities in Human Spontaneous Abortions	
Honord, L.H.	47
Plasma Alpha-Feto Protein Levels and Its Relation to Duration of Oral Contraceptive Use	
Babu, S., Ramalakshmi, B.A. and Prema, K.	53
STS 557, A New Orally Active Progestin with Antiprogestational and Contracestational Properties in Rabbits	
Dettel, M. and Kurischko, A.	61
Further Studies on the Trichosanthin-Induced Termination of Pregnancy	
Lau, I.F., Saksena, S.K. and Chang, M.C.	77
Hormonal Effects of the 300 μ g Norethisterone (NET) Minipill. I. Daily Steroid Levels in 43 Subjects During a Pretreatment Cycle and During the Second Month of NET Administration	
Landgren, B.-M. and Diczfalusy, E.	87

CONTRACEPTION is published monthly by Geron-X, Inc.
Box 1108, Los Altos, California 94022, USA.

©1980, Geron-X, Inc.

Two Volumes per year

Personal Subscription \$ 60

Institutional Subscription \$100

Add \$7 for surface postage outside USA

Add \$16 for airmail USA. Add \$36 for airmail outside USA

Second-class postage paid at Los Altos, Calif. and at additional mailing office.

CONTRACEPTION

February 1980

Volume 21, Number 2

Effects of Contraceptive Steroids on Serum Lipoproteins and Cardiovascular Disease Scrutinized at Workshop in Bethesda Baggett, B. and Nash, H.A.	115
Acceptability of Drugs for Male Fertility Regulation: A Prospectus and Some Preliminary Data WHO Task Force on Psychosocial Research in Family Planning	121
The Effect of Rifampicin on the Pharmacokinetics of Ethynodiol-2 ^o in Women Back, D.J., Breckenridge, A.M., Crawford, F.E., Hall, J.M., MacIver, M., Orme, M.L'E., Rowe, P.H., Smith, E. and Watts, M.J.	135
The Pharmacokinetics of a Large (3 mg) Oral Dose of Ethynodiol-2 ^o in Women Back, D.J., Bolt, H.M., Breckenridge, A.M., Crawford, F.E., Orme, M.L'E., Rowe, P.H. and Schindler, A.E.	145
Patterns of Ovulation and Bleeding with a Low Levonorgestrel-Releasing Intrauterine Device Nilsson, C.G., Lähteenmäki, P. and Luukkainen, T.	155
Release of Norethisterone from a Bioabsorbable Implant in Female Bonnet Monkeys (<i>Macaca radiata</i>) Maitra, A., Joshi, U.M., Kholkute, S.D., Munshi, S.R., Gupta, G.N. and Tejuja, S.	165
The Influence of Scrotal Heating Prior to Vasectomy on Sperm Granuloma Formation and Testicular Activity Subhas, T. and Michaels, T.	175
Cyproterone Acetate and Seminal Vesicles in the Regulation of Male Fertility Nayyar, S.K. and Ghosh, T.	183
Ovulation Inhibition by Daily I.M. Administration of a Highly Active LH-RH Analog (D-Ser(TBU) ⁶ -LH-RH-(1-9)-Nonapeptide-Ethylamide) Baumann, R., Kuhl, H., Taubert, H.-D. and Sandow, J.	191
The Antigonadotropic Activity of <i>Lithospermum ruderale</i> . I. The Lack of Steroid-Like Activity at the Receptor Level Findley, W.E. and Jacobs, B.R.	199

CONTRACEPTION

March 1980

Volume 21, Number 3

A Randomized, Single Blind Comparative Trial of Norethindrone Enanthate and Depo-Medroxyprogesterone Acetate in Bangladesh Swenson I., Khan, A.R. and Jahan, F.A.	207
Release of 19-Nor-Testosterone Type of Contraceptive Steroids Through Different Drug Delivery Systems into Serum and Breast Milk of Lactating Women Toddywalla, V.S., Mehta, S., Virkar, K.D. and Saxena, B.N.	217
Levonorgestrel Plasma Concentrations and Hormone Profiles After Insertion and After One Year of Treatment with a Levonorgestrel-IUD Nilsson, C.G., Lähteenmäki, P. and Luukkainen, T.	225
Disposable Menstrual Regulation Kits in a Non-Throw-Away Economy Fortney, J.A. and Vengadasalam, D.	235
Use of Low-Dosage Oral Cyproterone Acetate As a Male Contraceptive Wang, C. and Yeung, K.K.	245
Early Pregnancy Interruption with Two 15-ME-PGF _{2a} Suppositories Lauersen, N.H. and Wilson, K.H.	273
Effects of Medroxyprogesterone Acetate on Serum Lipids, Protein, Glucose Tolerance and Liver Function in Thai Women Amatayakul, K., Sivassomboon, B. and Singkamani, R.	283
The Effect of Injectable Norethisterone Oenanthate on Ovarian Hormones in Thai Women Werawatgoompa, S., Vaivanijkul, B., Leepipatpaiboon, S., Channiyom, K., Virutamasen, P. and Dusitsin, N.	299
Levels of HCG in Subjects Using the Progestasert TM Intrauterine Progesterone Systems Custo, G.M., Carenza, L. and Pala, A.	311

CONTRACEPTION

April 1980

Volume 21, Number 4

Two-Year Rates for Nova T and Copper T in a Comparative Study Allonen, H., Luukkainen, T., Nielsen, N.C., Nygren, K.-G. and Pyörälä, T.	321
Five Years Private Practice Experience of Nulliparous Women Using Copper IUD's Smith, R.P., Goresky, D.M. and Etchell, D.M.	335
Quantitative Menstrual and Intermenstrual Blood Loss in Women Using Lippes Loop and Copper T Intrauterine Devices Shaw, S.T., Jr., Andrade, A.T.L., de Souza, J.P., Macaulay, L.K. and Rowe, P.J.	343
Analysis of a Study of Menses Induction Using a Vaginal Suppository Containing 3.0 mg 15(S)-15-Methyl-PGF _{2α} Methyl Ester Spilman, C.H., Gutknecht, G.D., Beuving, D.C. and Southern, E.M.	353
The Combined Use of Oral Medroxyprogesterone Acetate and Methyltestosterone in a Male Contraceptive Trial Programme Bain, J., Rachlis, V., Robert E. and Khait, Z.	365
Oral Levo-Norgestrel - Testosterone Effects on Spermatogenesis, Hormone Levels, Coagulation Factors and Lipoproteins in Normal Men Foegh, M., Damgaard-Pedersen, F., Gormsen, J., Knudsen, J.B. and Schou, G.	381
Medium Dose Cyproterone Acetate (CPA): Effects on Hormone Secretion and on Spermatogenesis in Men Moltz, L., Römmler, A., Post, K., Schwartz, U. and Hammerstein, J.	393
A Comparison of the Pharmacokinetic Properties of Three Estradiol Esters Oriowo, M.A., Landgren, B.-M., Stenström, B. and Diczfalusy, E.	415
Effect of HCG ^β -TT Immunization on Ovarian Morphology in Hamsters Implanted with Human Choriocarcinoma Knecht, M.	425
Microanalysis of Lipids in Discrete Brain Areas of the Rabbit Following Intramuscular Administration of Steroid Contraceptive Islam, F., Hasan, M., Rizvi, R. and Osman, S.M.	433

CONTRACEPTION

May 1980

Volume 21, Number 5

A Randomized, Double-Blind Study of Two Combined Oral Contraceptives Containing the Same Progestogen, But Different Estrogens	445
World Health Organization Task Force on Oral Contraceptives	445
Effects of Gossypol on the Fertility of Male Rats, Hamsters and Rabbits	461
Chang, M.C., Gu, Z. (Ku, C-P) and Saksena, S.K.	461
Chorionic Gonadotropin Prevents LRF-Agonist-Induced Luteolysis in the Human	471
Casper, R.F., Sheehan, K.L. and Yen, S.S.C.	471
Serum Phospholipid Fractionation After the Use of Long-Acting Progestational Contraceptives	479
Guirgis, F.K., El-Sawy, M., Abdel-Hay, M.M., Saleh, F.M. and Abdel-Gawad, A.H.E. ...	479
Selected Events Following Insertion of the Progestasert® System	491
Gibor, Y. and Mitchell, C.	491
Effects of Oral Contraceptives Containing 50 μ g Estrogen on Blood Coagulation in Non-Caucasian Women	505
Tsakok, F.H.M., Koh, S. and Ratnam, S.S.	505
Prototype for a New Class of Antifertility Agents, 3,5-Bis (Dimethylamino)-1,2,4-Dithiazolium Chloride	529
Hahn, D.W., McConnell, R.F. and McGuire, J.L.	529
STS 557 As an Interceptive in Rodents and Baboons	537
Oettel, M., Komor, A., Goncharov, N.P., Kurischko, A., Strecke, J. and Schubert, K. ...	537
Studies on the Mechanism of the Antifertility Activity of Human Chorionic Gonadotropin in Rodents	551
Hahn, D.W., Demers, L.M. and McGuire, J.L.	551

CONTRACEPTION

June 1980

Volume 21, Number 6

The Association of Depo-Medroxyprogesterone Acetate and Breast Cancer Greenspan, A.R., Hatcher, R.A., Moore, M., Rosenberg, M.J. and Ory, H.W.	563
Dilatation of the Cervix Prior to Vacuum Aspiration By Single Vaginal Administration of 15-Methyl-PGF 2α Methyl Ester Frankman, O., Bygdeman, M., Green, K., Moberg, P. and Sandberg, C-G	571
Actinomycetes in the Endometrium of IUD Users Aubert, J.M., Gobeaux-Castadot, M-J and Boria, M.C.	577
Electrochemical Vaginal-Oral Potentials During the Menstrual Cycle in Women Zipper, J., Bruzzone, M.E. and Angelo, S.	585
Clinical and Endocrinologic Study of Continuous Levonorgestrel administration from Subcutaneous Solid Polydimethylsiloxane Rods Roy, S., Stanczyk, F., Mishell, D.R., Jr., Lumkin, M. and Gentschein, E.	595
A Study of Interaction of a Low-Dose Combination Oral Contraceptive with Anti-Tubercular Drugs Joshi, J.V., Joshi, U.M., Sankolli, G.M., Gupta, K., Rao, A.P., Hazari, K., Sheth, U.K. and Saxena, B.N.	617
Clinical Evaluation of Long-Term Treatment with Levo-Norgestrel and Testosterone Enanthate in Normal Men Foegh, M., Nichol, K., Petersen, I.B. and Schou, G.	631
Effect of STS 557 on Semen Composition, Fertility and Sexual Behaviour of Male Rabbits Freund, H., Hesse, G. and Oettel, M.	641
Inhibition of LH-Induced Ovulation in the Rat by a Hormonal Antagonist Sairam, M.R.	651
Uterine and Kidney Aspartate Aminotransferase Activity in Ethinylestradiol- and Norgestrel-Treated Rats Williams, S.A. and Boots, L.R.	659
Author Index for Volume 21	665
Subject Index for Volume 21	667

CONTRACEPTION

INDEX TO VOLUME 22

AUTHOR INDEX

Ahmad, N., 573
Akerlund, M., 199
Akinla, O., 115
Amatayakul, K., 605
Annus, J., 9
Back, D.J., 495
Bates, M., 495
Begum, S.F., 573
Bergquist, C., 287, 341
Betrabet, S., 241
Black, T.R.L., 653
Bleumink, E., 25
Boonsiri, B., 397
Bowden, A., 495
Bowers, C.Y., 313
Brat, T., 9
Breckenridge, A.M., 495
Bremme, K., 471
Brenner, P.F., 85, 137
Bressler, R., 597
Bruijn, H.W.A., 359
Burton, F.G., 409
Bygdeman, M., 153, 471
Carrillo, D., 259
Cates, W., Jr., 513
Chenault, C.B., 369
Chowdhury, V., 241, 643
Chretien, F.C., 445
Christensen, N., 153, 471
Christian, C.D., 597
Chvapil, M., 325
Croxatto, H.B., 259, 583
Croxatto, H.-D., 259
Dagle, G.E., 409
Dawson, A.G., 505
de Gaetano, G., 249
de Gast, G.C., 25
Diaz, S., 259, 583
Dickerson, J., 597
Diethelm, P., 9
di Minno, G., 249
Dombrowicz, N., 537
Donati, M.B., 249
Dreyer, N.A., 123
Droegenmueller, W., 325
Dukes, M., 383
Edgren, R.A., 39
Elamsson, K., 583
El-Habashi, M., 549
El-Mahgoub, S., 271
El-Sahwi, S., 549
Englund, D., 71
Eskelson, C.D., 325
Folkers, K., 313
Fong, H.H.S., 183
Forshell, S., 383
Fotherby, K., 527
Free, M.J., 31
Friebel, K., 313
Gawish, S., 549
Gerretsen, G., 25
Gill, B.P., 63
Gillman, S., 295
Goebelmann, U., 85, 457
Goh, T.H., 389
Goldstuck, N.D., 653
Goldzieher, J.W., 369
Gopalkrishna, K., 241
Göser, R., 165
Gray, R.H., 9
Gréen, K., 153, 471
Gupta, K., 643
Gutknecht, G., 57
Hahnenberger, R., 349
Hall, M.J., 495
Hamberger, L., 383
Hansen, P.R., 369
Hariharan, M., 389
Haspels, A.A., 441
Hazari, K., 643
Heywood, R., 189
Hindriks, F.R., 359
Howe, G.R., 175
Huang, D.C., 623
Hümpel, M., 485
Humphrey, R.R., 39
Humphries, J., 313
Hutton, P., 505
Jänne, O., 19
Johansson, E.D.B., 349, 583
Jones, A.R., 505
Jones, D.C., 39

CONTRACEPTION

Jones, H., 495
Jones, W.R., 425
Jordan, J.H., 39
Joshi, J.V., 643
Joshi, U.M., 241, 643
Källfelt, B., 383
Kankeerati, W., 397
Keller, E., 165
Koetsawang, S., 527
Kremer, J., 25, 359
Krishna, U., 643
Ladanyi, S., 165
Laudánski, T., 199
Lewis, D.J., 189
Liao, W.C., 573
Lopes, A., 9
Lundström, V., 153, 471
MacIver, M., 495
Mandlekar, A., 643
Marrs, R.P., 137
Mathrubuthan, M., 527
Matin, S., 457
Mehta, S., 241
Miranda, P., 583
Mishell, D.R., Jr., 85, 137
Morrow, M.M., 31
Mussoni, L., 249
McCann, M.F., 573
McDaniel, E.R., 1
Nater, J.P., 25
Neau, C., 445
Nerenberg, C., 457
Newton, J., 9
Newton, J.R., 295
Nillius, S.J., 287, 341
Nilsson, O., 71
Nitichai, Y., 397
Öhman, L., 349
Orme, M., 495
Osman, M., 549
Owen, J.A., 325
Oyediran, M.A., 115
Paavonen, J., 107
Pangrazzi, J., 249
Parker, R.A., 1
Pastushok, C.A., 39
Pavez, M., 259
Pei-Zhu, Z., 561
Perucca, E., 495
Pholpramool, C., 673
Pizarro, E., 9
Pizzo, S.V., 123
Querido, L., 441
Quinteros, E., 259
Rainer, E., 485
Reel, J.R., 39
Reyers, I., 249
Richens, A., 495
Rienprayura, D., 397
Roncaglioni, M.C., 249
Rosati, S., 259
Roux, J.F., 57
Rowe, P.H., 495
Rowe, S.E., 409
Roy, S., 137
Sakowski, R., 39
Sankholi, G.M., 643
Saxena, B.N., 241, 643
Schindler, A.E., 165
Schircks, B., 313
Schneider, B.E., 369
Scholz, I., 9
Schulz, K.F., 513
Schwallie, P.C., 623
Shain, R.N., 213, 227
Sheth, U.K., 643
Sikov, M.R., 409
Simonetti, L., 259
Sivasomboon, B., 605
Skimens, E.W., 31
Skimens, W.E., 409
Smith, E., 495
Sornpaisarn, L., 673
Southern, E., 57
Spence, A., 653
Stanczyk, F.Z., 85, 457
Steward, R., 175
Stiffel, V., 325
Stoppelli, I., 485
Sureau, C., 445
Tan, C.H., 389
Tangkeow, P., 397
Thanangkul, O., 605
The, T.H., 25
Turner, L.F., 623
Umapathysivam, K., 425

CONTRACEPTION

Van de Walle, J., 537
Vesterinen, E., 107
Victor, A., 71
Virutamasen, P., 397
Voda, A.M., 63
Wadsworth, P.F., 189
Waller, D.P., 183
Weiner, E., 71
Wide, L., 287, 341

Wilde, K., 63
Wilks, J., W., 313
Williams, W.L., 659
Wilson, E.W., 9
Windsor, B.L., 39
Woutersz, T.B., 369
Ylöstalo, P., 19
Zaneveld, L.J.D., 183

CONTRACEPTION

INDEX TO VOLUME 22

SUBJECT INDEX

Abnormalities found on pelvic examination, intramuscular prostaglandin for failure of mid-trimester abortion by another method, 623

Abortion, oxytocin augmentation during second-trimester, 513

Abortion population, incidence of gonorrhea, 441

Activated factor X inhibitor activity, mestranol + lynestrenol (rat), 249

Acute salpingitis patients, use of IUD, 107

use of oral contraceptives, 107

Adverse reactions, intramuscular prostaglandin for failure of mid-trimester abortion by another method, 623

Agonist of LHRH, effect on luteal function, 287

inhibition of preovulatory gonadotropin secretion (monkey), 313

luteolysis prevented by HCG, 341

Alkylating agents, use in male fertility regulation (rat, hamster), 175

Ampicillin therapy, interaction with ethynodiol + norethisterone acetate, 643

Antagonistic analogues of LHRH, biological effects (rat, hamster, rabbit), 39

Anthropometric studies, DMPA users, 605

Anticonvulsant therapy, interaction with ethynodiol + levonorgestrel, 495

Antithrombin III activity, mestranol + lynestrenol (rat), 249

Antithrombin-III level, women with history of idiopathic thromboembolism, 123

Biochemical and protein composition of endometrium, effects of contraceptive agents, 425

Biological effects of antagonistic analogues of LHRH (rat, hamster, rabbit), 39

Bleeding pattern, clinical effects of ethynodiol estrogens with and without progestational agents, 369

effect of medroxyprogesterone acetate, 527

Blood and cerebrospinal fluid levels of 17 β -estradiol, after ocular and nasal administration (monkey), 349

Blood coagulation and idiopathic thromboembolism, 123

Blood levels of 17 β -estradiol, after ocular administration, 349

Blood pressure, clinical effects of ethynodiol estrogens with and without progestational agents, 369

effect of mestranol + lynestrenol (rat), 249

CONTRACEPTION

Body and organ weights, effect of LHRH antagonistic analogues (rat), 39
Body water compartmentalization studies, DMPA users, 605
Burst test parameters, measurement of condom strength, 31
Castration,
 effect on electrolyte composition of cauda epididymal plasma (rat), 673
 effect on electrolyte composition of epididymal spermatozoa (rat), 673
 effect on fertility (rat), 673
Cauda epididymal plasma, electrolyte composition after castration (rat), 673
Cell-mediated immunity, effect of hormonal contraceptives, 25
Cerebrospinal fluid and blood levels of 17 β -estradiol, after ocular and nasal administration (monkey), 349
Cervical dilatation,
 effect of 9-deoxo-16,16-dimethyl-9-methylene-PGE₂, 153
 use of prostaglandin E analogues, 471
Cervical mucus,
 effect of d-norgestrel-releasing intracervical device (primate), 409
 effect of norgestriene, 445
 α -Chlorohydrin (3-chloropropan-1,2-diol)
 inhibition of glycolysis in sperm (boar), 505
Clinical effects of ethynodiol diacetate on bleeding patterns, weight and blood pressure, 369
Clinical effects of ethynodiol diacetate + progestational agents on bleeding patterns, weight and blood pressure, 369
Clinical laboratory findings, d-norgestrel-releasing intra-cervical device (primate), 409
Clinical performance,
 noregestrel-T IUD, 271
 Nova-T and copper-T-200, 115
Clinical study,
 ethynodiol diacetate and ethynodiol diacetate + lynestrenol, 537
 norethisterone oenanthate, 397
Clinical trial, Neo Sampoon vaginal contraceptive tablets, 573
Combined oral contraceptives, effect on nucleic acid and protein composition of endometrial tissue, 425
Commercial vaginal contraceptives, improvement of efficacy with zinc (rabbit), 659
Comparative multicentre trial, IUDs inserted immediately following delivery of placenta, 9
Comparative study, clinical performance of Nova-T and copper-T-200, 115
Complication and treatment rates during second-trimester abortion, effect of oxytocin augmentation, 513
Complications post-sterilization, retrospective survey, 295
Condom strength and relationship to failure during use, 31

CONTRACEPTION

Copper 7,
 post-coital insertion, 653
 post-placental insertion, 9

Copper IUD, effect on nucleic acid and protein composition
 of endometrial tissue, 425

Copper-bearing IUDs, effect on serum iron indices and
 haemoglobin concentration, 389

Copper-releasing IUDs, Nova-T and copper-T-200, 115

Copper-T-200,
 clinical performance, 115, 271
 five years experience, 561
 gross appearance of IUD after five years of use, 561
 histological changes of endometrium, 561
 loss of copper from IUD, 561
 post-abortal insertion, 561

Creatinine excretion, DMPA users, 605

Cyproterone acetate (17-acetoxy-6-chloro-1 α -2 α -methylene-4,6-
 pregnadiene-3,20-dione)
 plasma concentration, 485
 transfer to milk during lactation, 485

Decidual cells, ultrastructural features after levonorgestrel-
 releasing intravaginal ring (monkey), 189

9-Deoxo-16,16-dimethyl-9-methylene-PGE₂,
 effect on uterine contractility, 153
 vaginal suppository for dilatation of cervix, 471
 vaginal suppository for mid-trimester abortion, 153
 vaginal suppository for termination of early pregnancy,
 471

Depot-medroxyprogesterone acetate (DMPA) (see also Medroxy-
 progesterone acetate)
 effect on serum high density lipoprotein cholesterol
 levels, 359
 use of quinesterol for control of vaginal bleeding
 irregularities, 1

Different doses of medroxyprogesterone acetate, pharmaco-
 kinetic study, 527

Dilatation of cervix,
 effect of 9-deoxo-16,16-dimethyl-9-methylene-PGE₂, 153
 use of prostaglandin E analogues, 471

Distribution, nonoxynol-9 (rabbit), 325

DMPA (depot-medroxyprogesterone acetate)

Duration of efficacy, norgestriene, 445

Early gestation termination, single vaginal suppository of
 (15S)-15-methyl-PGF₂ α methyl ester, 137

Early pregnancy termination,
 single vaginal suppository of 15(S)-15-methyl PGF₂ α
 (methyl ester), 57
 use of prostaglandin E analogues, 471

Ectopic pregnancy, association with progestagen-releasing
 IUDs, 259

Efficacy of intramuscular prostaglandin for failure of mid-
 trimester abortion by another method, 623

CONTRACEPTION

Electrolyte composition,
cauda epididymal fluid after castration (rat), 673
epididymal spermatozoa after castration (rat), 673

Endometrial changes, norgestrel-T IUD, 271

Endometrial effects, estradiol and levonorgestrel, 71

Endometrial estrogen and progestin receptors, effect of
progesterone-releasing IUD, 19

Endometrium, effects of contraceptive agents on biochemical
and protein composition, 425

Epididymal spermatozoa, effect on electrolyte composition
after castration (rat), 673

Escape ovulation due to missing pill intake, ethinyl estradiol
+ norethisterone acetate, 241

Estradiol, effects on endometrium, 71

17 β -Estradiol,
levels in blood and cerebrospinal fluid after ocular
and nasal administration (monkey), 349
levels in blood after ocular administration, 349

Estradiol and levonorgestrel, effects on endometrium, 71

Estradiol-benzoate + estradiol-phenylpropionate,
effect on plasma hormone concentrations, 165
postcoital contraception, 165

Estrogen receptors, effect of progesterone-releasing IUD, 19

Estrous cycle, effect of LHRH antagonistic analogues (rat),
39

Ethinylestradiol,
pharmacodynamics, 85
pharmacokinetics, 457
radioimmunoassay in presence of circulating norethindrone,
457

Ethinylestradiol + norethindrone,
effect on liver function tests, 597
pharmacodynamics of ethinylestradiol, 85
radioimmunoassay of ethinylestradiol, 457

Ethinyl estradiol + norethisterone acetate,
effect on plasma level of Ampicillin, 643
effect on plasma level of Metronidazole, 643
escape ovulation due to missing pill intake, 241
interaction with Ampicillin and Metronidazole, 643

Ethinylestradiol + norgestrel, pharmacodynamics of ethinyl-
estradiol, 85

Ethinylestradiol concentrations, following ethinylestradiol
+ norethindrone, 457

Ethinyl estradiol plasma level, effect of Ampicillin and
Metronidazole treatments, 643

Ethinylestradiol single oral dose, pharmacodynamics of
ethinylestradiol, 85

Ethinylestradiol + lynestrenol and ethinylestradiol,
clinical, histological and stereomorphometric
studies, 537

Ethinylestradiol + d-norgestrel, influence on cell-mediated
immunity, 25

CONTRACEPTION

Ethinylestradiol and ethinyloestradiol + lynestrenol, clinical, histological and stereomorphometric studies, 537
oral contraceptive of normophasic type, 537

Ethinylestradiol and ethinyloestradiol + mestranol acetate, influence on cell-mediated immunity, 25

Ethynodiol, clinical effects on bleeding patterns, weight and blood pressure, 369

Ethynodiol + levonorgestrel, interaction of phenobarbital and other anticonvulsants, 495

Ethynodiol + megestrol acetate, clinical effects on bleeding patterns, weight and blood pressure, 369

Ethynodiol + norethindrone acetate, clinical effects on bleeding patterns, weight and blood pressure, 369

Ethynodiol + norethisterone acetate, interaction of phenobarbital and other anticonvulsants, 495

Ethynodiol + dl-norgestrel, clinical effects on bleeding patterns, weight and blood pressure, 369

Ethynodiol levels, interaction of phenobarbital and other anticonvulsants, 495

Excretion, nonoxynol-9 (rat, rabbit), 325

Failure during use, relationship to strength of condoms, 31

Failure of mid-trimester abortion by another method, use of intramuscular (15S)-15-methyl PGF_{2α}, 623

Fallopian tubes, effect of Lippes loop on sperm recovery, 549

Fertility, effect of castration (rat), 673

Fibrinolytic activity, mestranol + lynestrenol (rat), 249
women with history of idiopathic thromboembolism, 123

First trimester pregnancy, uterine effects of vasopressin analogue, 199

Five years experience, Copper T 200, 561

Five years of use, levonorgestrel subdermal implants, 583

Foaming vaginal insert, contraceptive effect (rabbit), 659

Foaming vaginal tablets, clinical trial of Neo Sampo, 573

Glycolysis inhibition in sperm, α-chlorhydrin (boar), 505

Gonadotropin secretion inhibition during preovulatory phase by LHRH agonist (monkey), 313

Gonorrhea, incidence in abortion population, 441

Gossypol, contraceptive effect (rabbit), 659
spermicidal activity, 183

Gossypol acetic acid, spermicidal activity, 183

Gossypol-polyvinylpyrrolidone, spermicidal activity, 183

Gross appearance of TCu 200 after five years of use, 561

Haemoglobin concentration, effect of copper-bearing IUDs, 389

HCG (human chorionic gonadotropin)

HCG β-subunit level, use of 15(S)-15-methyl PGF_{2α} (methyl ester), 57

HCG levels, use of prostaglandin E analogues, 471

CONTRACEPTION

HCG prevents luteolysis induced by LHRH agonist, 341
 β hCG levels, use of (15S)-15-methyl-PGF₂ α methyl ester, 137
Hemostatic system, effect on plasmatic and vascular factors
by mestranol + lynestrenol (rat), 249
High density lipoprotein cholesterol levels, effect of
DMPA, 359
Histological changes of endometrium, TCu 200, 561
Histological study, ethinylestradiol and ethinylestradiol
+ lynestrenol, 537
Histopathological findings, d-norgestrel-releasing intra-
cervical device (primate), 409
Hormonal contraceptives, effect on immune reactivity, 25
Hormone concentrations, after postcoital contraception
with estradiol-benzoate + estradiol-phenylpro-
pionate, 165
Human chorionic gonadotropin (HCG)
Hypertonic saline, effect of oxytocin augmentation, 513
Idiopathic thromboembolism,
 Antithrombin-III level, 123
 fibrinolytic activity, 123
Idiopathic thromboembolism and blood coagulation, 123
Immune reactivity, effect of hormonal contraceptives, 25
Impact of reversibility on selection of tubal sterilization,
 27
Implant contraception, levonorgestrel, 583
Incidence of gonorrhea in abortion population, 441
Inert IUD, effect on nucleic acid and protein composition
 of endometrial tissue, 425
Infrastructure of cervical mucus, effect of norgestriene,
 445
Inhibition of glycolysis in sperm, α -chlorohydrin (boar), 505
Inhibition of preovulatory gonadotropin secretion by LHRH
 agonist (monkey), 313
Injectable contraceptive,
 depot-medroxyprogesterone acetate, 1, 359
 medroxyprogesterone acetate, 25, 527, 605
 norethisterone oenanthate, 397
Intracervical device, d-norgestrel-releasing (primate), 409
Intrauterine device (IUD)
 copper, 425
 copper 7, 9, 389, 653
 copper-T-200, 115, 259, 271, 561
 inert, 425
 levonorgestrel-releasing, 259, 271
 Lippes loop size D, 9
 Lippes loop type C, 549
 megestrol acetate-releasing, 259
 Multiload 250, 389
 norethindrone-releasing, 259

CONTRACEPTION

norgestrel T, 271
norgestriene-releasing, 259
Nova-T, 115
post-partum copper T, 9
post-placental insertion, 9
progesterone-releasing, 19
R2323-releasing, 259
T-220C, 389
use in patients with acute salpingitis, 107

Intravaginal ring,
estradiol- and levonorgestrel-releasing, 71
levonorgestrel-releasing, 71
levonorgestrel-releasing (monkey), 189

Iron indices, effect of copper-bearing IUDs, 389

IUD (intrauterine device)

IUD insertion, post-coital, 653

Lactation,
appearance of nonoxynol-9 in milk (rat), 325
transfer of cyproterone acetate in milk, 485

Laparoscopy sterilization, analysis of morbidity and post-sterilization complications, 295

Laparotomy sterilization, analysis of morbidity and post-sterilization complications, 295

Levonorgestrel,
effects on endometrium, 71
radioimmunoassay, 583
subdermal implants, 583

Levonorgestrel levels, following implantation of silastic capsules containing levonorgestrel, 583

Levonorgestrel-releasing intravaginal ring, ultrastructural study of decidual cells (monkey), 189

Levonorgestrel-releasing IUD,
association with ectopic pregnancy, 259
clinical performance, 271
endometrial changes, 271
menstrual pattern, 271
quantitation of menstrual blood loss, 271

LHRH (luteinizing hormone releasing hormone)

LHRH agonist,
effect on luteal function, 287
inhibition of preovulatory gonadotropin secretion (monkey), 313

LHRH agonist-induced luteolysis prevented by HCG, 341

LHRH analogue,
Boc-[Ser(Bz1)¹, des-His², D-Trp⁶]-LHRH, 39
D-Ser(TBU)⁶-EA¹⁰-LHRH, 287, 311
[(<Glu-Pro)¹, D-Phe², D-Trp^{3,6}]-LHRH, 313
Z-[Gln¹, des-His², D-Pse⁶, des-Gly¹⁰]-LHRH ethylamide, where D-Pse=threo-D-phenylserine, 39

LHRH antagonistic analogues, biological effects (rat, hamster, rabbit), 39

CONTRACEPTION

Lippes loop,
effect on recovery of sperm from fallopian tubes, 549
effect on white blood corpuscles in tubal washings, 549

Lippes loop size D, post-placental insertion, 9

Liver function tests, effect of ethinyl estradiol + norethindrone, 597

Long-term levonorgestrel subdermal implants, plasma levels of levonorgestrel, 583

Loss of copper from TCu 200 after five years of use, 561

Luminal epithelium, endometrial effects of estradiol and levonorgestrel, 71

Luteal function, effect of LHRH agonist, 287

Luteal phase institution of LHRH agonist treatment, 287

Luteinizing hormone releasing hormone (LHRH)

Luteolysis induced by LHRH agonist prevented by HCG, 341

Luteolytic effect, PGF₂α analogue in non-pregnant women, 383

8-Lysine-vasopressin, uterine effects in first trimester pregnancy, 199

Male fertility regulation, use of alkylating agents (rat, hamster), 175

Malondialdehyde generation, mestranol + lynestrenol (rat), 249

Manganese, contraceptive effect (rabbit), 659

Mechanism of weight gain, DMPA users, 605

Medroxyprogesterone acetate (see also Depot-medroxyprogesterone acetate)
anthropometric studies, 605
body water compartmentalization studies, 605
creatinine excretion, 605
effect on bleeding pattern, 527
effect on ovarian function, 527
influence on cell-mediated immunity, 25
mechanism of weight gain, 605
nitrogen balance study, 605
pharmacokinetic study of different doses, 527

Megestrol acetate-releasing IUD, association with ectopic pregnancy, 259

Menstrual blood loss, norgestrel-T IUD, 271

Menstrual cycle, serum phosphorus levels, 63

Menstrual pattern, norgestrel-T IUD, 271

Menstrual regulation, use of prostaglandin E analogues, 471

Mestranol, clinical effects on bleeding patterns, weight and blood pressure, 369

Mestranol + lynestrenol, effect on plasmatic and vascular factors of hemostatic system (rat), 249

Mestranol + megestrol acetate, clinical effects on bleeding patterns, weight and blood pressure, 369

Mestranol + norethindrone, pharmacodynamics of ethinyl-estradiol, 85

Mestranol + norethindrone acetate, clinical effects on bleeding patterns, weight and blood pressure, 369

Mestranol + dl-norgestrel, clinical effects on bleeding patterns, weight and blood pressure, 369

CONTRACEPTION

Metabolic study, norethisterone oenanthate, 397
Metabolism, nonoxynol-9 (rabbit), 325
Metronidazole therapy, interaction with ethinyl estradiol + norethisterone acetate, 643
Mid-trimester abortion, use of 9-deoxo-16,16-dimethyl-9-methylene-PGE₂ suppository, 153 use of intramuscular (15S)-15-methyl PGF₂α for failure of another method, 623
Milk, appearance of nonoxynol-9 during lactation (rat), 325 transfer of cyproterone acetate during lactation, 485
Missing pill intake, escape ovulation during treatment with ethinyl estradiol + norethisterone acetate, 241
Morbidity post-sterilization, retrospective survey, 295
"Morning after" injection, estradiol-benzoate + estradiol-phenylpropionate, 165
Multicentre trial, IUDs inserted immediately following delivery of placenta, 9
Myometrial effects of vasopressin analogue in first trimester pregnancy, 199
N-α-triglycyl-(8-lysine)-vasopressin, uterine effects in first trimester pregnancy, 199
Nasal administration of 17β-estradiol, levels in blood and cerebrospinal fluid (monkey), 349
Neo Sampo (active ingredient, p-methoxyphenyl polyoxyethylene (8.8) ether)
Neo Sampo vaginal contraceptive tablets, clinical trial, 573
Nitrogen balance study, DMPA users, 605
Nonoxynol-9 (nonylphenoxypoly (ethyleneoxy) ethanol) intravaginal absorption, distribution, metabolism and excretion (rat, rabbit), 325
Non-pregnant women, luteolytic effect of PGF₂α analogue, 383
Norethindrone, pharmacokinetics, 457
Norethindrone concentrations, following ethinylestradiol + norethindrone, 457
Norethindrone removal before radioimmunoassay of ethinyl-estradiol, 457
Norethindrone-releasing IUD, association with ectopic pregnancy, 259
Norethisterone oenanthate, clinical and metabolic study, 397
Norethisterone plasma level, effect of Ampicillin and Metronidazole treatments, 643
d-Norgestrel-releasing intracervical device, clinical laboratory findings (primate), 409 effect on cervical mucus (primate), 409 effect on serum progesterone levels (primate), 409 gross and histopathological findings (primate), 409
Norgestrel-T IUD, clinical performance, 271

CONTRACEPTION

Norgestrienone,
duration of efficacy, 445
effect on infrastructure of cervical mucus, 445
effect on spermatozoa, 445
Norgestrienone-releasing IUD, association with ectopic pregnancy, 259
Normophasic contraceptive, ethinyloestradiol and ethinyl-oestradiol + lynestrenol, 537
Nova-T IUD, clinical performance, 115
Nucleic acid and protein composition of endometrial tissue, use of combined oral contraceptives, 425
use of copper IUD, 425
use of inert IUD, 425
Objections concerning permanent sterilization, 213
Objections concerning reversible sterilization, 213
Objections to tubal sterilization, what reversibility can and cannot overcome, 213
Occlusion times of aortic loop, mestranol + lynestrenol (rat), 249
Ocular administration of 17 β -estradiol, levels in blood, 349
levels in blood and cerebrospinal fluid (monkey), 349
Oral contraceptive, combination type, 425
ethinyl estradiol + norethindrone, 85, 597
ethinyl estradiol + norethisterone acetate, 241, 643
ethynodiol + norgestrel, 85
ethinyloestradiol + d-norgestrel, 25
ethinyloestradiol and ethinyloestradiol + lynestrenol, 537
ethinyloestradiol and ethinyloestradiol + mestranol acetate, 25
ethynodiol, 369
ethynodiol + levonorgestrel, 495
ethynodiol + megestrol acetate, 369
ethynodiol + norethindrone acetate, 369
ethynodiol + norethisterone acetate, 495
ethynodiol + dl-norgestrel, 369
mestranol, 369
mestranol + megestrol acetate, 369
mestranol + norethindrone, 85
mestranol + norethindrone acetate, 369
mestranol + dl-norgestrel, 369
norgestrienone, 445
use in patients with acute salpingitis, 107
Ovarian function, effect of medroxyprogesterone acetate, 527
Ovulation, effect of LHRH antagonistic analogues (rat, hamster, rabbit), 39
Ovulation due to missing pill intake, ethinyl estradiol + norethisterone acetate, 241

CONTRACEPTION

Oxytocin augmentation,
complication and treatment rates during second-trimester abortion, 513
hypertonic saline instillation, 513
PGF_{2α} instillation, 513

Oxytocin, augmentation during second-trimester abortion, 513

PG (prostaglandin)

PGF_{2α} analogue, luteolytic effect in non-pregnant women, 383

PGF_{2α} instillation, effect of oxytocin augmentation, 513

Pharmacodynamics of ethinylestradiol,
ethinylestradiol + norethindrone, 85
ethinylestradiol + norgestrel, 85
mestranol + norethindrone, 85
single oral dose of ethinylestradiol, 85

Pharmacokinetic study of different doses of medroxyprogesterone acetate, 527

Pharmacokinetics,
ethinylestradiol, 457
norethindrone, 457

Phenobarbital therapy,
interaction with ethinylestradiol + levonorgestrel, 495
interaction with ethinylestradiol + norethisterone acetate, 495

16-Phenoxy- ω -17,18,19,20-tetranor PGE₂ methyl sulfonylamide,
intramuscular injections for dilatation of cervix, 471
intramuscular injections for termination of early pregnancy, 471

Phosphorus, serum levels during menstrual cycle, 63

Plasmatic and vascular factors of hemostatic system, effect of mestranol + lynestrenol (rat), 249

Plasminogen activator activity, mestranol + lynestrenol (rat), 249

Post-abortal insertion, copper T 200, 561

Postcoital contraception, estradiol-benzoate + estradiol-phenylpropionate, 165

Post-coital IUD insertion, 653

Post-partum T, post-placental insertion, 9

Post-placental insertion of IUD, 9

Post-sterilization complications, retrospective survey, 295

Post-sterilization morbidity, retrospective survey, 295

Potential impact of reversibility on selection of tubal sterilization, 227

Preovulatory gonadotropin secretion inhibition, LHRH agonist (monkey), 313

Progestagen-releasing IUD, association with ectopic pregnancy, 259

Progesterone levels,
effect of LHRH agonist, 341
effect of LHRH agonist + HCG, 341

CONTRACEPTION

effect of d-norgestrel-releasing intracervical device (primate), 409
effect of PGF_{2α} analogue in non-pregnant women, 383
use of (15S)-15-methyl-PGF_{2α}methyl ester, 57, 137
Progesterone-releasing IUD, endometrial estrogen and progestin receptors, 19
Progestin receptors, effect of progesterone-releasing IUD, 19
Prostacyclin activity, mestranol + lynestrenol, 249
Prostaglandin (PG)
Prostaglandin analogue,
 9-deoxo-16,16-dimethyl-9-methylene-PGE₂, 153, 471
 16-phenoxy-ω-17,18,19,20-tetranor PGE₂ methyl sulfonylamine, 471
 (15S)-15-methyl-PGF_{2α} methyl ester, 57, 137
 (15S)-15-methyl PGF_{2α} (THAM), 623
Prostaglandin E analogues, termination of early pregnancy and dilatation of cervix, 471
Protein and nucleic acid composition of endometrial tissue, use of combined oral contraceptives, 425
use of copper IUD, 425
use of inert IUD, 425
Quinesterol (3-cyclopentyl ether of ethinyloestradiol)
 effect on vaginal bleeding pattern during DMPA treatment, 1
R2323 (13-ethyl-17α-ethinyl-17β-hydroxygon-4,9,11-triene-3-one)
R2323-releasing IUD, association with ectopic pregnancy, 259
Rabbit vaginal contraception method, 659
Radioimmunoassay of ethinylestradiol, presence of circulating norethindrone, 457
Retrospective survey of sterilization, analysis of morbidity and post-sterilization complications, 295
Reversible sterilization, potential impact on selection of tubal sterilization, 227
(15S)-15-methyl-PGF_{2α} free acid levels, use of (15S)-15-methyl-PGF_{2α} methyl ester, 137
(15S)-15-methyl-PGF_{2α} methyl ester,
 suppository for termination of early gestation, 137
 suppository for termination of early pregnancy, 57
15(S)-15-methyl PGF_{2α} peripheral levels, use of 15(S)-15-methyl PGF_{2α} (methyl ester), 57
(15S)-15-methyl PGF_{2α} (THAM), intramuscular use for failure of mid-trimester abortion by another method, 623
Salpingitis patients,
 use of IUD, 107
 use of oral contraceptives, 107
Scanning electron microscopic study of luminal epithelium, endometrial effects of estradiol and levonorgestrel, 71
Second-trimester abortion, oxytocin augmentation, 513
Serum high density lipoprotein cholesterol levels, effect of DMPA, 359

CONTRACEPTION

Serum phosphorus levels during menstrual cycle, 63
Sex hormone binding globulin capacity, interaction of phenobarbital and other anticonvulsants with oral contraceptive therapy, 495
Sperm, inhibition of glycolysis by α -chlorohydrin (boar), 505
Sperm penetration test, effect of norgestrienone, 445
Sperm recovery from fallopian tubes, effect of Lippes loop, 549
Spermatozoa, effect of norgestrienone, 445
Spermicidal effect of gossypol, 183
Stereomorphometric study, ethinyl oestradiol and ethinyl-oestradiol + lynestrenol, 537
Sterilization, analysis of morbidity and post-sterilization complications, 295
potential impact of reversibility on acceptability, 227
reasons for objection, 213
Steroid receptor levels, effect of progesterone-releasing IUD, 19
Strength and relationship to failure of condoms during use, 31
Subdermal implants, levonorgestrel, 71, 583
TEPA (tris-1-aziridinylphosphine oxide), use in male fertility regulation (rat, hamster), 175
Termination of early gestation, single vaginal suppository of (15S)-15-methyl-PGF₂ α methyl ester, 137
Termination of early pregnancy, single vaginal suppository of 15(S)-15-methyl PGF₂ α (methyl ester), 57
use of prostaglandin E analogues, 471
Termination of mid-trimester pregnancy, use of 9-deoxo-16,16-dimethyl-9-methylene-PGE₂, 153
use of intramuscular (15S)-15-methyl PGF₂ α for failure of another method, 623
Thio-TEPA (triethylene phosphoramide), use in male fertility regulation (rat, hamster), 175
Tissue distribution, nonoxynol-9 (rabbit), 325
Transferrin saturation, effect of copper-bearing IUDs, 389
Treatment rates and complication during second-trimester abortion, effect of oxytocin augmentation, 513
Tubal sterilization, objections, 213
potential impact of reversibility, 227
Ultrastructural features of progestagen-induced decidual cells (monkey), 189
Use-effectiveness, Nova-T and copper-T-200, 115
Uterine contractility, effect of 9-deoxo-16,16-dimethyl-9-methylene-PGE₂, 153
Uterine effects of vasopressin analogue in first trimester pregnancy, 199
Vaginal absorption, nonoxynol-9 (rabbit), 325


CONTRACEPTION

Vaginal bleeding pattern, effect of quinesterol during DMPA treatment, 1
Vaginal contraceptive, effect of zinc salts (rabbit), 659
Vaginal contraceptive tablets, clinical trial of Neo Sampoon, 573
Valium, contraceptive effect (rabbit), 659
Vascular and plasmatic factors of hemostatic system, effect of mestranol + lynestrenol (rat), 249
Vasopressin analogue,
 8-lysine-vasopressin, 199
 myometrial effects in first trimester pregnancy, 199
 N- α -triglycyl-(8-lysine)-vasopressin, 199
Weight, clinical effects of ethinyl estrogens with and without progestational agents, 369
Weight gain, mechanism in DMPA users, 605
White blood corpuscles in tubal washings, effect of Lippes loop, 549
WHO, Task Force on IUD for Fertility Regulation, 9
Zinc salts, effect in vaginal econtraceptives (rabbit), 659

Volume 22, 1980
July-December, 1980
ISSN 0010-7824

CONTRACEPTION

AN INTERNATIONAL JOURNAL



DANIEL R. MISHELL, Jr., M.D.—Editor

Publisher: GERON-X, INC., LOS ALTOS, CALIF.

EDITOR

Daniel R. Mishell, Jr., M.D.
Dept. of Obstetrics and Gynecology
University of Southern California School of Medicine
1240 North Mission Road
Los Angeles, California 90033

EDITORIAL ASSISTANT

Elfi J. Martin

BOARD OF ASSOCIATE EDITORS

Wendy Baldwin, Ph.D.
Behavioral Sciences Branch
Center for Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014

Gerald S. Bernstein, Ph.D., M.D.
Associate Professor
Department of Obstetrics and
Gynecology
USC School of Medicine
Los Angeles, California 90033

M.C. Chang, Ph.D., Sc.D.
Senior Scientist
Worcester Foundation for
Experimental Biology
Shrewsbury, Massachusetts 01545

Philip A. Corfman, M.D.
Director of Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014

Jwe Goebelmann, M.D.
Director of the Reproductive
Endocrinology Laboratory
Nomen's Hospital
1240 North Mission Road
Los Angeles, California 90033

Joseph W. Goldzieher, M.D.
Director, Division of Clinical
Sciences
Southwest Foundation for
Research and Education
San Antonio, Texas 78228

Roy O. Greep, Ph.D.
Director
Laboratory of Human Reproduction
& Reproductive Biology
Harvard Medical School
45 Shattuck Street
Boston, Massachusetts 02115

Roy Hertz, M.D., Ph.D.
Research Professor
Departments of Pharmacology
and Obstetrics and Gynecology
George Washington University

Medical Center
Washington, D.C. 20037

William D. Odell, M.D., Ph.D.
Professor and Chairman
Department of Medicine
Harbor General Hospital
U.C.L.A. School of Medicine
Torrance, California 90509

C. Alvin Paulsen, M.D.
Professor of Medicine
Department of Medicine
University of Washington
School of Medicine
Seattle, Washington 98114

John J. Sciarra, M.D., Ph.D.
Chief of Staff
Prentice Women's Hospital and
Maternity Center
333 East Superior Street
Chicago, Illinois 60611

Sheldon Segal, Ph.D.
Director
Population Division
Rockefeller Foundation
1133 Avenue of the Americas
New York, New York 10036

William N. Spellacy, M.D.
Professor and Head
Department of Obstetrics
and Gynecology
The Abraham Lincoln
School of Medicine
University of Illinois
Medical Center
840 South Wood Street
Chicago, Illinois 60612

Howard J. Tatum, Ph.D., M.D.
Associate Director
Center for Biomedical Research
Rockefeller University
York Avenue & 66th Street
New York, N.Y. 10021

CONTRACEPTION

July 1980

Volume 22, Number 1

The Use of Quinesterol for the Control of Vaginal Bleeding Irregularities Caused by DMPA Parker, R.A. and McDaniel, E.B.	1
Comparative Multicentre Trial of Three IUDs Inserted Immediately Following Delivery of the Placenta WHO Task Force on Intrauterine Devices for Fertility Regulation	9
Endometrial Estrogen and Progestin Receptors in Women Bearing a Progesterone- Releasing Intrauterine Device Jänne, O. and Ylöstalo, P.	19
Immune Reactivity of Women on Hormonal Contraceptives. Phytohemagglutinin and Concanavalin-A Induced Lymphocyte Response Gerretsen, G., Kremer, J., Bleumink, E., Nater, J.P., de Gast, G.C. and The, T.H.	25
Relationship Between Condom Strength and Failure During Use Free, M.J., Skuens, E.W. and Morrow, M.M.	31
The Biological Effects of Two Antagonistic Analogs of Luteinizing Hormone Releasing Hormone Reel, J.R., Humphrey, R.R., Jones, D.C., Jordan, J.H., Pastushok, C.A., Sakowski, R., Windsor, B.L. and Edgren, R.A.	39
The Effect of a 15(S)-15-Methyl Prostaglandin F ₂ α (Methyl Ester) Suppository Upon Termination of Early Pregnancy Roux, J.F., Southern, E. and Gutknecht, G.	57
Serum Phosphorus During the Menstrual Cycle Voda, A.M., Wilde, K. and Gill, B.P.	63
Endometrial Effects of Levonorgestrel and Estradiol: A Scanning Electron Microscopic Study of the Luminal Epithelium Nilsson, O., Englund, D., Weiner, E. and Victor, A.	71
Serum Levels of Ethinylestradiol Following Its Ingestion Alone or in Oral Contraceptive Formulations Brenner, P.F., Goebelmann, U., Stanczyk, F.Z. and Mishell, D.R., Jr.	85
Letters to the Editor	97

CONTRACEPTION

August 1980

Volume 22, Number 2

Intrauterine Contraceptive Device Use in Patients With Acute Salpingitis Paavonen, J. and Vesterinen, E.....	107
A Comparative Study of the Clinical Performance of Two Copper-Releasing IUDs, Nova-T and Copper-T-200 in Lagos, Nigeria Oyediran, M.A. and Akinla, O.....	115
Blood Coagulation and Idiopathic Thromboembolism Among Fertile Women Dreyer, N.A. and Pizzo, S.V.....	123
Termination of Early Gestation With a Single Vaginal Suppository of (15S)-15-Methyl-Prostaglandin F ₂ ^α Methyl Ester Roy, S., Brenner, P.F., Marrs, R.P. and Mishell, D.R., Jr.....	137
Mid-Trimester Abortion by Vaginal Administration of 9-Deoxy-16, 16-Dimethyl-9-Methylene-PGE ₂ Bygdeman, M., Christensen, N., Gréen, K. and Lundström, V.....	153
Postcoital Contraception With an Injectable Estrogen Preparation (ORG 369 - 2) Schindler, A.E., Ladanyi, S., Gøser, R. and Keller, E.....	165
Fertility Regulation in Male Rats and Hamsters With Alkylating Agents Howe, G.R. and Steward, R.....	175
<u>In Vitro</u> Spermicidal Activity of Gossypol Waller, D.P., Zaneveld, L.J.D. and Fong, H.H.S.....	183
The Ultrastructural Features of Progestagen-Induced Decidual Cells in the Rhesus Monkey (<i>Macaca mulatta</i>) Wadsworth, P.F., Lewis, D.J. and Heywood, R.....	189
Uterine Effects of N- α -Triglycyl-(8-Lysine)-Vasopressin and 8-Lysine- Vasopressin in the First Trimester of Pregnancy Laudánski, T. and Akerlund, M.....	199
Announcement.....	209
Announcement.....	210
Announcement.....	211

CONTRACEPTION

September 1980

Volume 22, Number 3

Objections to Tubal Sterilization: What Reversibility Can and Cannot Overcome Shain, R.N.....	213
The Potential Impact of Reversibility on Selection of Tubal Sterilization Shain, R.N.....	227
'Escape' Ovulation in Women Due to the Missing of Low Dose Combination Oral Contraceptive Pills Chowdhury, V., Joshi, U.M., Gopalkrishna, K., Betrabet, S., Mehta, S. and Saxena, B.N....	241
Plasmatic and Vascular Factors of the Hemostatic System in Rats Receiving an Estrogen- Progestogen Combination Roncaglioni, M.C., di Minno, G., Pangrazzi, J., Reyers, I., Mussoni, L., de Gaetano, G., and Donati, M.B.....	249
Ectopic Pregnancies Associated With Low Dose Progestagen-Releasing IUDs Diaz, S., Croxatto, H.B., Pavez, M., Quinteros, E., Carrillo, D., Simonetti, L., Croxatto, H.D. and Rosati, S.....	259
The Norgestrel-T IUD El-Mahgoub, S.....	271
Effects of a Luteinizing Hormone-Releasing Hormone Agonist on Luteal Function in Women Bergquist, C., Nilius, S.J. and Wide, L.....	287
A Retrospective Survey of Female Sterilization for the Years 1968 to 1973, Analysis of Morbidity and Post-Sterilization Complications for 5 Years Newton, J.R. and Gillman, S.....	295
Inhibition of Preovulatory Gonadotropin Secretion in the Rhesus Monkey by [\langle Glu-Pro] ¹ , D-Phe ² ,D-Trp ^{3,6}]LHRH Wilks, J.W., Folkers K., Bowers, C.Y., Humphries, J., Schircks, B. and Friebel, K.....	313
Studies on Nonoxynol-9. II. Intravaginal Absorption, Distribution, Metabolism and Excretion in Rats and Rabbits Chvapil, M., Eskelson, C.D., Stiffel, V., Owen, J.A. and DroegeMueller, W.....	325

CONTRACEPTION

October 1980

Volume 22, Number 4

Luteolysis Induced by a Luteinizing Hormone-Releasing Hormone Agonist is Prevented by Human Chorionic Gonadotropin	
Bergquist, C., Nillius, S.J. and Wide, L.....	341
17 β -Estradiol Levels in Blood and Cerebrospinal Fluid After Ocular and Nasal Administration in Women and Female Rhesus Monkeys (<i>Macaca mulatta</i>)	
Öhman, L., Hahnberger, R. and Johansson, E.D.B.....	349
Serum High Density Lipoprotein Cholesterol Levels in Women Using a Contraceptive Injection of Depot-Medroxyprogesterone Acetate	
Kremer, J., de Bruijn, H.W.A. and Hindriks, F.R.....	359
Clinical Effects of Ethynodiol-Diol, Used With and Without Progestational Agents, on Bleeding Patterns, Weight and Blood Pressure	
Goldzieher, J.W., Chenuault, C.B., Woutersz, T.B., Schneider, B.E. and Hansen, P.R.....	369
A Luteolytic Effect of a Prostaglandin F _{2α} Analogue in Non Pregnant Women ?	
Hamberger, L., Källfelt, B., Forshell, S. and Dukes, M.....	383
A Longitudinal Study of Serum Iron Indices and Haemoglobin Concentration Following Copper-IUD Insertion	
Goh, T.H., Hariharan, M. and Tan, C.H.....	389
A Clinical and Metabolic Study of Norethisterone Oenanthate in Thai Women	
Virutamasen, P., Nitichai, Y., Tangkeow, P., Kankeerati, W., Rienprayura, D. and Boonsiri, B.....	397
Effects of d-Norgestrel-Releasing Intracervical Devices in the Nonhuman Primate, <i>Erythrocebus patas</i>	
Dagle, G.E., Sikov, M.R., Rowe, S.E., Burton, F.G. and Skiens, W.E.....	409
Effects of Contraceptive Agents on the Biochemical and Protein Composition of Human Endometrium	
Umapathysivam, K. and Jones, W.R.....	425
The Incidence of Gonorrhea in an Abortion Population	
Querido, L. and Haspels, A.A.....	441

CONTRACEPTION

November 1980

Volume 22, Number 5

Experimental Study of Cervical Blockage Induced by Continuous Low-Dose Oral Progestogens Chretien, F.C., Sureau, C. and Neau, C.....	445
Radioimmunoassay of Plasma Ethinylestradiol in the Presence of Circulating Norethindrone Stanczyk, F.Z., Gale, J.A., Goebelmann, U., Nerenberg, C. and Matin, S.....	457
A Comparison of Two Stable Prostaglandin E Analogues for Termination of Early Pregnancy and for Cervical Dilatation Bygdeman, M., Bremme, K., Christensen, N., Lundström, V. and Grén, K.....	471
Transfer of Cyproterone Acetate to the Milk of Lactating Women Stopelli, I., Rainer, E. and Humpel, M.....	485
The Interaction of Phenobarbital and Other Anticonvulsants With Oral Contraceptive Steroid Therapy Back, D.J., Bates, M., Bowden, A., Breckenridge, A.M., Hall, M.J., Jones, H., MacIver, M., Orme, M., Perucca, E., Richens, A., Rowe, P.H. and Smith, E.....	495
Inhibition of Glycolysis in Boar Sperm by α -Chlorhydrin Hutton, P., Dawson, A.G. and Jones, A.R.....	505
Oxytocin Augmentation of Second-Trimester Abortion: Safe or Hazardous? Cates, W., Jr. and Schulz, K.F.....	513
Pharmacokinetic Study of Different Doses of Depo Provera Fotherby, K., Koetsawang, S. and Mathrubutham, M.....	527
Combined Clinical, Histological and Stereomorphometric Studies with a New Oral Contraceptive of Normophasic Type: Fysioquens Dombrowicz, N. and Van de Walle, J.....	537
Effect of Lippes Loop on Sperm Recovery From Human Fallopian Tubes El-Habashi, M., El-Sahwi, S., Gawish, S. and Osman, M.....	549
Erratum.....	557
Announcement.....	559

CONTRACEPTION

December 1980

Volume 22, Number 6

Five Years Experience With the Copper T 200 in Shanghai - 856 Cases Pei-zhu, Z.....	561
A Clinical Trial of Neo Sampoov Vaginal Contraceptive Tablets Begum, S.F., Liao, W.C., McCann, M.F. and Ahmed, N.....	573
Plasma Levels of Levonorgestrel in Women During Longterm Use of Norplants Croxatto, H.B., Diaz, S., Miranda, P., Elamsson, K. and Johansson, E.D.B.....	583
Liver Function Tests and Low-Dose Estrogen Oral Contraceptives Dickerson, J., Bressler, R. and Christian, C.D.....	597
A Study of the Mechanism of Weight Gain in Medroxyprogesterone Acetate Users Amatayakul, K., Sivasomboon, B. and Thanangkul, O.....	605
Use of Intramuscular Prostaglandin for Failure of Mid-Trimester Abortion by Another Method Schwallie, P.C., Huang, D.C. and Turner, L.F.....	623
A Study of Interaction of Low-Dose Combination Oral Contraceptive With Ampicillin and Metronidazole Joshi, J.V., Joshi, U.M., Sankholi, G.M., Krishna, U., Mandlekar, A., Chowdhury, V., Hazari, K., Gupta, K., Sheth, U.K. and Saxena, B.N.....	643
Post-Coital Intrauterine Device Insertion - A Further Evaluation Black, T.R.L., Goldstuck, N.D. and Spence, A.....	653
New Antifertility Agents Active in the Rabbit Vaginal Contraception (RVC) Method Williams, W.L.....	659
Fertility and Electrolyte Composition of the Rat Cauda Epididymal Plasma and Spermatozoa Before and After Castration Pholpramool, C. and Sornpaisarn, L.....	673
Announcement.....	683
Announcement.....	684
Author Index for Volume 22.....	685
Subject Index for Volume 22.....	689

